

CITATION REPORT

List of articles citing

Signatures of mutational processes in human cancer

DOI: 10.1038/nature12477
Nature, 2013, 500, 415-21.

Source: <https://exaly.com/paper-pdf/54914659/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2217	.		
2216	Calcium-induced contraction of the rhizoplast of a quadriflagellate green alga. 1978 , 202, 975-7		161
2215	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. 2017 , 6, 169-177		2
2214	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. 2017 , 6, 186-195		8
2213	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. 2012 , 83, 20		6
2212	Physical chemistry: Combs for molecules. <i>Nature</i> , 2013 , 502, 307-8	50.4	4
2211	Genomics: Comparisons across cancers. <i>Nature</i> , 2013 , 502, 306-7	50.4	8
2210	Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. 2013 , 155, 948-62		478
2209	High-resolution network biology: connecting sequence with function. 2013 , 14, 865-79		65
2208	Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. 2013 , 27, 2513-30		174
2207	The causes and consequences of genetic heterogeneity in cancer evolution. <i>Nature</i> , 2013 , 501, 338-45	50.4	1473
2206	The Cancer Genome Atlas Pan-Cancer analysis project. 2013 , 45, 1113-20		3933
2205	Cancer genomics: Signature analysis suggests cancer origins. 2013 , 14, 677		1
2204	Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. 2013 , 231, 413-23		73
2203	Genomics: Mutator catalogues. 2013 , 13, 681		2
2202	Genetics: Signatures of mutational processes in cancer-a big step closer. 2013 , 10, 545		3
2201	Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. 2013 , 5, 87		33

2200	Tackling the diversity of triple-negative breast cancer. 2013 , 19, 6380-8	120
2199	High-throughput gene expression and mutation profiling: current methods and future perspectives. 2013 , 8, 401-6	11
2198	Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. 2013 , 4, 2873	236
2197	APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. 2013 , 73, 7222-31	123
2196	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. 2013 , 110, 18250-5	377
2195	RASAL1 in thyroid cancer: wisdom from an old foe. 2013 , 105, 1597-9	9
2194	Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline. 2013 , 110, 20152-7	51
2193	A primate-specific microRNA enters the lung cancer landscape. 2013 , 110, 18748-9	6
2192	The era of genomic medicine. 2013 , 13, 594-601	11
2191	Localized structural frustration for evaluating the impact of sequence variants. 2016 , 44, 10062-10073	9
2190	Correction: Corrigendum: Signatures of mutational processes in human cancer. <i>Nature</i> , 2013 , 502, 258-258.4	6
2189	Will we cure cancer by sequencing thousands of genomes?. 2013 , 6, 57	2
2188	Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. 2013 , 14, R126	65
2187	Cancer Mutations and their Tissue-specific Nature. 2013 , 06,	
2186	An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing. 2013 , 8, e78823	5
2185	Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. 2013 , 8, e82770	31
2184	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. 2014 , 7, 1689-704	54
2183	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction. 2014 , 9, e97787	62

2182	Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis. 2014 , 9, e107105	13
2181	[A reductionist approach of cancer]. 2014 , 30, 683-7	0
2180	Value of oncogenes for the prediction of brain metastases at initial diagnosis: a review of published data. 2014 , 29, e291-300	
2179	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. 2014 , 3,	229
2178	Toward a systematic understanding of cancers: a survey of the pan-cancer study. 2014 , 5, 194	19
2177	Mechanisms of base substitution mutagenesis in cancer genomes. 2014 , 5, 108-46	32
2176	Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. 2014 , 8, 1745-51	40
2175	Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. 2014 , 23	3
2174	Validation of Next Generation Sequencing Cancer Panels for Clinical Somatic Mutation Profiling-- Identification of Source of Variations and Artifacts using FFPE Tissues. 2014 , 01,	2
2173	Dormancy of growth-stunted malignant melanoma: sustainable and smoldering patterns. 2014 , 8, 252	7
2172	[Stochastic phenomena and the tumoral process]. 2014 , 30, 693-8	0
2171	MYC and the control of DNA replication. 2014 , 4,	38
2170	Blind source separation for groundwater pressure analysis based on nonnegative matrix factorization. 2014 , 50, 7332-7347	27
2169	Insights into cancer biology through next-generation sequencing. 2014 , 14 Suppl 6, s71-7	2
2168	Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions. 2014 , 193, 4888-94	8
2167	Gene signature profiling of gynaecological malignancies. 2014 , 7, 252-255	
2166	A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. 2014 , 15, 473	52
2165	Empirical prediction of genomic susceptibilities for multiple cancer classes. 2014 , 111, 1921-6	5

2164	FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. 2014 , 15, 480	209
2163	Molecular targeting of mutagenic AID and APOBEC deaminases. 2014 , 13, 171-2	2
2162	Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. 2014 , 3, e27817	157
2161	The genome of the chicken DT40 bursal lymphoma cell line. 2014 , 4, 2231-40	18
2160	High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. 2014 , 3, e28836	70
2159	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. 2014 , 3, e27560	34
2158	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. 2014 , 5, 5191	47
2157	RNAi therapies: drugging the undruggable. 2014 , 6, 240ps7	176
2156	Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. 2014 , 14, 115	31
2155	Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. 2014 , 111, 2548-53	509
2154	Global optimization of somatic variant identification in cancer genomes with a global community challenge. 2014 , 46, 318-319	36
2153	Processed pseudogenes acquired somatically during cancer development. 2014 , 5, 3644	68
2152	Human germline and pan-cancer variomes and their distinct functional profiles. 2014 , 42, 11570-88	20
2151	APOBEC3 signature mutations in chronic lymphocytic leukemia. 2014 , 28, 1929-32	18
2150	Is homologous recombination really an error-free process?. 2014 , 5, 175	75
2149	C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. 2014 , 24, 1624-36	125
2148	Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis. 2014 , 6, 1208-19	21
2147	A quick guide to genomics and bioinformatics training for clinical and public audiences. 2014 , 10, e1003510	13

2146	DNA bending facilitates the error-free DNA damage tolerance pathway and upholds genome integrity. 2014 , 33, 327-40	48
2145	Stratified Medicine for Pancreatic Cancer. 2014 , 807-814	
2144	Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. 2014 , 5,	131
2143	Brain tumors and syndromes in children. 2014 , 45, 137-61	10
2142	'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients. 2014 , 7, 1761-1766	7
2141	Hydroxymethylated cytosines are associated with elevated C to G transversion rates. 2014 , 10, e1004585	28
2140	Increased and imbalanced dNTP pools symmetrically promote both leading and lagging strand replication infidelity. 2014 , 10, e1004846	44
2139	Predicting cancer prognosis using functional genomics data sets. 2014 , 13, 85-8	9
2138	ContrastRank: a new method for ranking putative cancer driver genes and classification of tumor samples. 2014 , 30, i572-8	16
2137	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. 2014 , 5, 252	31
2136	Can we move towards personalised pancreatic cancer therapy?. 2014 , 8, 335-8	3
2135	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. 2014 , 15, 190	179
2134	Genome destabilizing mutator alleles drive specific mutational trajectories in <i>Saccharomyces cerevisiae</i> . 2014 , 196, 403-12	16
2133	Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. 2014 , 15, 1943-6	5
2132	High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. 2014 , 51, 545-52	55
2131	SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. 2014 , 7, 2006-18	280
2130	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. 2014 , 159, 1524-37	186
2129	Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. 2014 , 74, 6224-35	27

2128	Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. 2014 , 371, 2230-2	37
2127	Single nucleotide variations: biological impact and theoretical interpretation. 2014 , 23, 1650-66	64
2126	TCR repertoires of intratumoral T-cell subsets. 2014 , 257, 72-82	51
2125	Genetic basis for clinical response to CTLA-4 blockade in melanoma. 2014 , 371, 2189-2199	2802
2124	Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. 2014 , 135, 2362-9	30
2123	Stochastic simulation in systems biology. 2014 , 12, 14-25	55
2122	Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. 2014 , 775-776, 48-54	24
2121	Molecular and genetic diversity in the metastatic process of melanoma. 2014 , 233, 39-50	47
2120	Identification of somatic alterations in stage I lung adenocarcinomas by next-generation sequencing. 2014 , 53, 289-98	9
2119	Cancer prevention by adult-onset calorie restriction after infant exposure to ionizing radiation in B6C3F1 male mice. 2014 , 135, 1038-47	20
2118	Hypermutation in human cancer genomes: footprints and mechanisms. 2014 , 14, 786-800	274
2117	Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. 2014 , 28, 2276-82	86
2116	Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?. 2014 , 7, 941-51	113
2115	Age-related clonal hematopoiesis associated with adverse outcomes. 2014 , 371, 2488-98	2314
2114	Evolving concepts of tumor heterogeneity. 2014 , 4, 69	49
2113	Survival regression by data fusion. 2014 , 2, 47-53	3
2112	High resolution mapping of modified DNA nucleobases using excision repair enzymes. 2014 , 24, 1534-42	65
2111	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. 2014 , 42, 6106-27	53

2110	Deep sequencing of the X chromosome reveals the proliferation history of colorectal adenomas. 2014 , 15, 437	0
2109	Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. 2014 , 6, 81	26
2108	Breast cancer: is there a viral connection?. 2014 , 21, 373-81	10
2107	Carcinoma of unknown primary site. 2014 , 371, 2040	13
2106	Somatic hypermutation at A/T-rich oligonucleotide substrates shows different strand polarities in Ung-deficient or -proficient backgrounds. 2014 , 34, 2176-87	16
2105	DNA repair inhibition by UVA photoactivated fluoroquinolones and vemurafenib. 2014 , 42, 13714-22	18
2104	NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. 2014 , 7, 556-69	60
2103	When defense turns into attack: Antiviral cytidine deaminases linked to somatic mutagenesis in HPV-associated cancer. 2014 , 1, e29914	4
2102	The genomic landscape of pediatric Ewing sarcoma. 2014 , 4, 1326-41	302
2101	Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. 2014 , 5, 3756	66
2100	Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties. 2014 , 42, 1095-110	53
2099	Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. 2014 , 9, 1228-34	77
2098	h5vc: scalable nucleotide tallies with HDF5. 2014 , 30, 1464-6	2
2097	Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. 2014 , 4, 78	60
2096	Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome. 2014 , 20, 6127-40	72
2095	Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history. 2014 , 20, 4912-24	21
2094	TERT promoter mutations in cancer development. 2014 , 24, 30-7	167
2093	Genetic screens in mice for genome integrity maintenance and cancer predisposition. 2014 , 24, 1-7	1

2092	MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. <i>Nature</i> , 2014 , 508, 215-21	50.4	326
2091	Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets. 2014 , 36, 552-60		8
2090	Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. 2014 , 24, 52-60		299
2089	Evolution of the cancer stem cell model. 2014 , 14, 275-91		1462
2088	Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. 2014 , 343, 1470-5		163
2087	Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. 2014 , 21, 1119-31		230
2086	Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm. 2014 , 35, 643-53		14
2085	Epistatic interactions and drug response. 2014 , 232, 255-63		19
2084	The challenge of intratumour heterogeneity in precision medicine. 2014 , 276, 41-51		50
2083	The emerging role of RNA and DNA editing in cancer. 2014 , 1845, 308-16		20
2082	Individualized medicine from prewomb to tomb. 2014 , 157, 241-53		194
2081	Beyond histology: translating tumor genotypes into clinically effective targeted therapies. 2014 , 20, 2264-75		51
2080	Clustered and genome-wide transient mutagenesis in human cancers: Hypermutation without permanent mutators or loss of fitness. 2014 , 36, 382-393		39
2079	Cancer Immunotherapy Meets Oncology. 2014 ,		
2078	Molecular Testing in Cancer. 2014 ,		1
2077	The ABCs of T Cell Receptor Gene Therapy. 2014 , 117-126		
2076	TP53 mutations in human cancer: database reassessment and prospects for the next decade. 2014 , 35, 672-88		191
2075	Mutational patterns in the breast cancer mitochondrial genome, with clinical correlates. 2014 , 35, 1046-54		49

2074	Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. 2014 , 46, 583-7	360
2073	Prioritization of neurodevelopmental disease genes by discovery of new mutations. 2014 , 17, 764-72	115
2072	Cancer as a metabolic disease: implications for novel therapeutics. 2014 , 35, 515-27	263
2071	DNA testing and molecular screening for colon cancer. 2014 , 12, 377-81	25
2070	Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. 2014 , 14, 108-19	354
2069	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. 2014 , 5, 2997	564
2068	Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage. 2014 , 343, 437-440	116
2067	Rapid learning for precision oncology. 2014 , 11, 109-18	64
2066	The evolution of the unstable cancer genome. 2014 , 24, 61-7	52
2065	Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration. 2014 , 11, 71-2	4
2064	APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. 2014 , 88, 1308-17	66
2063	Realizing the promise of cancer predisposition genes. <i>Nature</i> , 2014 , 505, 302-8	50.4 340
2062	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. 2014 , 46, 116-25	244
2061	Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. 2014 , 46, 1267-73	491
2060	Evidence of a cancer type-specific distribution for consecutive somatic mutation distances. 2014 , 53 Pt A, 79-83	4
2059	Variation in genomic landscape of clear cell renal cell carcinoma across Europe. 2014 , 5, 5135	123
2058	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. 2014 , 46, 1258-63	215
2057	Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. 2014 , 32, 1106-12	62

2056	A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility. 2014, 5, 5348	17
2055	The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. 2014, 346, 945-9	246
2054	The physician scientist: balancing clinical and research duties. 2014, 15, 1092-4	23
2053	A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif. 2014, 471-473, 105-16	20
2052	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. 2014, 5, 5224	176
2051	Pan-cancer patterns of DNA methylation. 2014, 6, 66	107
2050	Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. 2014, 24, 1751-64	111
2049	Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. 2014, 24, 1740-50	187
2048	Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. 2014, 16, 211	183
2047	Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. 2014, 6, 24	50
2046	Cancer genomics: one cell at a time. 2014, 15, 452	202
2045	Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. 2014, 5, 3981	13
2044	Nucleic acid-based tissue biomarkers of urologic malignancies. 2014, 51, 173-99	28
2043	Melanocytes are selectively vulnerable to UVA-mediated bystander oxidative signaling. 2014, 134, 1083-1090	18
2042	Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. 2014, 5, 3365	103
2041	Acquired and intrinsic resistance in cancer immunotherapy. 2014, 8, 1132-9	133
2040	Chemical biology approaches to target validation in cancer. 2014, 17, 87-100	30
2039	A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. 2014, 5, 5129	90

2038	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. 2014 , 5, 5006	120
2037	Genomic uracil homeostasis during normal B cell maturation and loss of this balance during B cell cancer development. 2014 , 34, 4019-32	20
2036	Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. 2014 , 5, 405-13	99
2035	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. <i>Nature</i> , 2014 , 512, 155-60	730
2034	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. 2014 , 1, 75-86	65
2033	Having a direct look: analysis of DNA damage and repair mechanisms by next generation sequencing. 2014 , 329, 35-41	8
2032	The somatic genomic landscape of chromophobe renal cell carcinoma. 2014 , 26, 319-330	521
2031	Mutational signatures in Helicobacter pylori-induced gastric cancer: lessons from new sequencing technologies. 2014 , 147, 267-9	7
2030	Viral infection-oxidative stress/DNA damage-aberrant DNA methylation: separate or interrelated events responsible for genetic instability and childhood ALL development?. 2014 , 1846, 226-31	6
2029	Personalized medicine in hematology - A landmark from bench to bed. 2014 , 10, 70-7	9
2028	Integrated genomic characterization of adrenocortical carcinoma. 2014 , 46, 607-12	423
2027	Transcription and recombination: when RNA meets DNA. 2014 , 6,	45
2026	When old hematopoietic stem cells get damaged. 2014 , 15, 399-400	2
2025	The genomic and epigenomic landscapes of AML. 2014 , 51, 259-72	11
2024	Identification of 33 candidate oncogenes by screening for base-specific mutations. 2014 , 111, 1657-62	24
2023	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. 2014 , 346, 256-9	659
2022	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. 2014 , 5, 3401	132
2021	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. 2014 , 12, 140	30

2020	The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. 2014 , 15, 417	61
2019	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. 2014 , 4, 554-63	279
2018	Visualization of recombination-mediated damage bypass by template switching. 2014 , 21, 884-92	101
2017	Molecular oncology testing in resource-limited settings. 2014 , 16, 601-11	10
2016	Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. 2014 , 9, 1104-14	36
2015	Genome-wide analysis of noncoding regulatory mutations in cancer. 2014 , 46, 1160-5	367
2014	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. 2014 , 128, 449-52	28
2013	Cancer: evolution within a lifetime. 2014 , 48, 215-36	146
2012	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. 2014 , 346, 251-6	752
2011	Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. 2014 , 146, 211-20	67
2010	C2c: turning cancer into chronic disease. 2014 , 6, 38	12
2009	Pancreatic cancer stroma: friend or foe?. 2014 , 25, 711-2	134
2008	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. 2014 , 46, 487-91	208
2007	Toxicogenomics and cancer susceptibility: advances with next-generation sequencing. 2014 , 32, 121-58	30
2006	Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. 2014 , 46, 872-6	258
2005	Expanding the computational toolbox for mining cancer genomes. 2014 , 15, 556-70	146
2004	The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. 2014 , 27, 835-8	76
2003	Patterns and processes of somatic mutations in nine major cancers. 2014 , 7, 11	47

2002	Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. 2014 , 20, 3842-8	96
2001	Mechanisms underlying mutational signatures in human cancers. 2014 , 15, 585-98	514
2000	BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. 2014 , 50, 2668-76	50
1999	Determinants of mutation rate variation in the human germline. 2014 , 15, 47-70	204
1998	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. 2014 , 40, 1089-95	19
1997	Genome sequencing of normal cells reveals developmental lineages and mutational processes. <i>Nature</i> , 2014 , 513, 422-425	50.4 249
1996	Cancer Bioinformatics. 2014 ,	4
1995	Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?. 2014 , 346, 163-71	104
1994	Pancreatic cancer genomics. 2014 , 24, 74-81	40
1993	Evolving understanding of the CLL genome. 2014 , 51, 177-87	22
1992	Exploration of liver cancer genomes. 2014 , 11, 340-9	138
1991	Accumulation of somatic mutations in TP53 in gastric epithelium with <i>Helicobacter pylori</i> infection. 2014 , 147, 407-17.e3	95
1990	Chemical biology on the genome. 2014 , 22, 4356-70	9
1989	Deamination intensity profiling of human APOBEC3 protein activity along the near full-length genomes of HIV-1 and MoMLV by HyperHRM analysis. 2014 , 448, 168-75	7
1988	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. 2014 , 8, 150-8	34
1987	The causes of replication stress and their consequences on genome stability and cell fate. 2014 , 30, 154-64	85
1986	Error-free versus mutagenic processing of genomic uracil--relevance to cancer. 2014 , 19, 38-47	42
1985	Translational informatics in personalized medicine: an update for 2014. 2014 , 11, 339-349	

1984	Molecular genetics of clear-cell renal cell carcinoma. 2014 , 32, 1968-76	213
1983	The omics of triple-negative breast cancers. 2014 , 60, 122-33	44
1982	Physiology of the read-write genome. 2014 , 592, 2319-41	3
1981	Steadily improving survival in lung cancer. 2014 , 15, 331-7	17
1980	High-definition reconstruction of clonal composition in cancer. 2014 , 7, 1740-1752	135
1979	Cancer initiation with epistatic interactions between driver and passenger mutations. 2014 , 358, 52-60	20
1978	Molecular classification of breast cancer. 2014 , 465, 1-14	106
1977	Tissue specificity in DNA repair: lessons from trinucleotide repeat instability. 2014 , 30, 220-9	31
1976	APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. 2014 , 7, 1833-41	235
1975	Break-induced replication is a source of mutation clusters underlying kataegis. 2014 , 7, 1640-1648	121
1974	Mutational context and diverse clonal development in early and late bladder cancer. 2014 , 7, 1649-1663	94
1973	Circulating tumor cells: Cancer's deadly couriers. 2014 , 67, 26-30	17
1972	Antioxidant and anticancer activities of Moringa oleifera leaves. 2014 , 8, 318-325	66
1971	Modelling mutational landscapes of human cancers in vitro. 2014 , 4, 4482	68
1970	Identification of 2R-ohnologue gene families displaying the same mutation-load skew in multiple cancers. 2014 , 4, 140029	10
1969	Rapid analysis of chromosome aberrations in mouse B lymphocytes by PNA-FISH. 2014 ,	6
1968	Differential and limited expression of mutant alleles in multiple myeloma. 2014 , 124, 3110-7	42
1967	Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. 2014 , 124, 3887-95	18

1966	From drug response profiling to target addiction scoring in cancer cell models. 2015 , 8, 1255-64	9
1965	UV signature mutations. 2015 , 91, 15-26	225
1964	Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme. 2015 , 43, 9340-9	24
1963	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. 2015 , 106, 945-50	61
1962	Tumorstammzellen im Melanom. 2015 , 13, 118-124	
1961	Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. 2015 , 35, 1786-800	23
1960	Mutational Analysis of Ionizing Radiation Induced Neoplasms. 2015 , 12, 1915-26	25
1959	Tumor Heterogeneity in Breast Cancer. 2015 , 22, 294-302	8
1958	Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. 2015 , 5, 12566	68
1957	The Molecular Basis of Haematological Malignancies. 2015 , 314-331	
1956	Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types. 2015 , 5, 13413	74
1955	Modeling cancer metabolism on a genome scale. 2015 , 11, 817	122
1954	The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. 2015 , 125, 600-5	14
1953	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. 2015 , 126, 2491-501	134
1952	3D-DIP-Chip: a microarray-based method to measure genomic DNA damage. 2015 , 5, 7975	28
1951	MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. 2015 , 5, 13321	79
1950	Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review). 2015 , 12, 6405-14	6
1949	Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study. 2015 , 5, 17564	12

1948	Mutated tumor alleles are expressed according to their DNA frequency. 2014 , 4, 4743	26
1947	Principles of immunotherapy. 2015 , 13, 670-2	6
1946	Enhancing cancer clonality analysis with integrative genomics. 2015 , 16 Suppl 13, S7	3
1945	Cell injury, retrodifferentiation and the cancer treatment paradox. 2015 , 36, 7365-74	1
1944	APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions. 2015 , 13, 1103-1109	57
1943	Computational methods and resources for the interpretation of genomic variants in cancer. 2015 , 16 Suppl 8, S7	11
1942	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. 2015 , 7, 98	64
1941	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. 2015 , 3, 88	27
1940	Stochasticity and determinism in cancer creation and progression. 2015 , 1,	3
1939	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. 2015 , 237, 363-78	72
1938	The Ruesch Center Symposium 2014: Fighting a Smarter War against Cancer Using Immunotherapy. 2015 , 4, 63-68	
1937	Can Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. 2015 , 15, 792	11
1936	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. 2015 , 8, 58	29
1935	Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. 2015 , 2, 11	30
1934	Targeting tumor suppressor genes for cancer therapy. 2015 , 37, 1277-86	41
1933	HSP90 inhibitors decrease AID levels and activity in mice and in human cells. 2015 , 45, 2365-76	11
1932	Imaging T Cells In Vivo. 2015 , 56, 1135-6	1
1931	Polyomavirus BK and prostate cancer: a complex interaction of potential clinical relevance. 2015 , 25, 366-78	17

- 1930 From eels to the importance of cancer biobanks. **2015**, 1, FSO65
- 1929 The IMPAKT of breast cancer research: fundamental science and applied medicine. **2015**, 1, FSO69
- 1928 Hypermethylation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. **2015**, 87, 1754-60 23
- 1927 Immunotherapies for bladder cancer: a new hope. **2015**, 25, 586-96 13
- 1926 Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions. **2015**, 21, 450-64 30
- 1925 PharmaForum. **2015**, 38, 466-467
- 1924 Precision medicine for metastatic breast cancer. **2015**, e2-7 13
- 1923 Age-related somatic mutations in the cancer genome. **2015**, 6, 24627-35 68
- 1922 Comparative genomic analysis reveals bilateral breast cancers are genetically independent. **2015**, 6, 31820-9 15
- 1921 Chronic lung injury by constitutive expression of activation-induced cytidine deaminase leads to focal mucous cell metaplasia and cancer. **2015**, 10, e0117986 6
- 1920 Biomarkers of Response to Immune Modulatory Therapies in Cancer. **2015**, 06,
- 1919 OECC-EACR precision medicine for cancer: Conference report 1-4 March 2015, Luxembourg. **2015**, 9, 519
- 1918 APOBEC3 Interference during Replication of Viral Genomes. **2015**, 7, 2999-3018 23
- 1917 Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. **2015**, 3, 420-8 14
- 1916 Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. **2015**, 2, 363-387 20
- 1915 Mitochondrial Dysfunction and Disturbed Coherence: Gate to Cancer. **2015**, 8, 675-95 15
- 1914 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. **2015**, 6, 505 71
- 1913 Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. **2015**, 6, 516 51

1912	APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts. 2015 , 10, e0120089	27
1911	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. 2015 , 10, e0126762	14
1910	Simultaneous DNA and RNA Mapping of Somatic Mitochondrial Mutations across Diverse Human Cancers. 2015 , 11, e1005333	74
1909	A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events. 2015 , 11, e1004583	14
1908	Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level. 2015 , 11, e1005277	26
1907	Mutagenesis by AID: Being in the Right Place at the Right Time. 2015 , 11, e1005489	1
1906	Similar Squamous Cell Carcinoma Epithelium microRNA Expression in Never Smokers and Ever Smokers. 2015 , 10, e0141695	12
1905	Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer. 2015 , 10, e0144528	5
1904	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. 2015 , 2015, 595363	17
1903	Personalized targeted therapy for esophageal squamous cell carcinoma. 2015 , 21, 7648-58	35
1902	FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis. 2015 , 6, 3409-19	22
1901	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. 2015 , 6, 17543-58	45
1900	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. 2015 , 6, 15772-87	197
1899	AID/APOBEC deaminases and cancer. 2015 , 2, 320-33	85
1898	Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. 2015 , 06,	4
1897	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. 2015 , 34, 5699-708	114
1896	Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. 2015 , 12, 623-30	201
1895	The emerging complexity of gene fusions in cancer. 2015 , 15, 371-81	382

1894	T cell exclusion, immune privilege, and the tumor microenvironment. 2015 , 348, 74-80	1156
1893	Organic chemistry. Practical olefin hydroamination with nitroarenes. 2015 , 348, 886-91	299
1892	Frequency and distribution of Notch mutations in tumor cell lines. 2015 , 15, 311	14
1891	Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. 2015 , 348, 880-6	983
1890	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. 2015 , 21, 3347-3355	184
1889	CTCF/cohesin-binding sites are frequently mutated in cancer. 2015 , 47, 818-21	286
1888	Breaking bad: R-loops and genome integrity. 2015 , 25, 514-22	210
1887	Cell Fusion Connects Oncogenesis with Tumor Evolution. 2015 , 185, 2049-60	44
1886	Oncotator: cancer variant annotation tool. 2015 , 36, E2423-9	332
1885	Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. 2015 , 174, 987-97	19
1884	Theoretical considerations for thresholds in chemical carcinogenesis. 2015 , 765, 56-67	25
1883	Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. 2015 , 16, 601-12	123
1882	SomnClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering. 2015 , 16, 125	23
1881	Genomic landscape of rat strain and substrain variation. 2015 , 16, 357	66
1880	Lung cancer in the era of precision medicine. 2015 , 21, 2213-20	109
1879	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. 2015 , 6, 6605	245
1878	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4 890
1877	A one-page summary report of genome sequencing for the healthy adult. 2015 , 18, 123-9	32

1876	The somatic autosomal mutation matrix in cancer genomes. 2015 , 134, 851-64	14
1875	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. 2015 , 6, 6744	666
1874	Peto's paradox and the hallmarks of cancer: constructing an evolutionary framework for understanding the incidence of cancer. 2015 , 370,	33
1873	From Mutational Mechanisms in Single Cells to Mutational Patterns in Cancer Genomes. 2015 , 80, 117-37	7
1872	A tale of two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell renal cell carcinoma. 2015 , 2, e979686	2
1871	Base damage, local sequence context and TP53 mutation hotspots: a molecular dynamics study of benzo[a]pyrene induced DNA distortion and mutability. 2015 , 43, 9133-46	11
1870	Deciphering the Code of the Cancer Genome: Mechanisms of Chromosome Rearrangement. 2015 , 1, 217-230	35
1869	Local DNA dynamics shape mutational patterns of mononucleotide repeats in human genomes. 2015 , 43, 5065-80	11
1868	Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. 2015 , 43, 5307-17	27
1867	BayesPI-BAR: a new biophysical model for characterization of regulatory sequence variations. 2015 , 43, e147	11
1866	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. 2015 , 6, 10001	199
1865	Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. 2015 , 6, 10131	67
1864	Stem cells and healthy aging. 2015 , 350, 1199-204	181
1863	Mitochondrial dysfunction and longevity in animals: Untangling the knot. 2015 , 350, 1204-7	162
1862	Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. 2015 , 6, 8940	175
1861	Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. 2015 , 49, 243-67	75
1860	Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. 2015 , 6, 8866	139
1859	Activation-induced deoxycytidine deaminase (AID) co-transcriptional scanning at single-molecule resolution. 2015 , 6, 10209	22

1858	Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. 2015 , 13, 267-76	198
1857	A processual model for functional analyses of carcinogenesis in the prospective cohort design. 2015 , 85, 494-7	2
1856	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. 2016 , 108, djv427	111
1855	Bladder Tumor Heterogeneity: The Impact on Clinical Treatment. 2015 , 95, 1-8	18
1854	[What opportunities does Immuno-oncology indicate for overarching long-term survival?]. 2015 , 38 Suppl 3, 6-11	1
1853	Whole genome sequencing as a means to assess pathogenic mutations in medical genetics and cancer. 2015 , 72, 1463-71	20
1852	Targeted therapies in melanoma. 2015 , 24, 347-58	5
1851	The mutational landscape of endometrial cancer. 2015 , 30, 25-31	30
1850	Mutations of epigenetic regulatory genes are common in thymic carcinomas. 2014 , 4, 7336	85
1849	Intratumoral heterogeneity and consequences for targeted therapies. 2015 , 102, 17-23	13
1848	The cancer genomics and global cancer genome collaboration. 2015 , 60, 65-70	3
1847	The value of monitoring to control evolving populations. 2015 , 112, 1007-12	35
1846	Genetic lesions in diffuse large B-cell lymphomas. 2015 , 26, 1069-1080	52
1845	Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. 2015 , 33, 786-809	91
1844	BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. 2015 , 57, 636-647	245
1843	Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. 2015 , 29, 1243-52	26
1842	Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft. 2015 , 100, 725-35	19
1841	Cell-of-origin chromatin organization shapes the mutational landscape of cancer. <i>Nature</i> , 2015 , 518, 360-364	344

1840	DNA replication stress as a hallmark of cancer. 2015 , 10, 425-48	389
1839	Melanoma stem cells. 2015 , 13, 118-24	8
1838	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. 2015 , 6, 6051	211
1837	Translational cancer research: balancing prevention and treatment to combat cancer globally. 2015 , 107, 353	26
1836	Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. 2015 , 6, 6120	139
1835	Do mutational dynamics in stem cells explain the origin of common cancers?. 2015 , 16, 111-2	6
1834	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. 2015 , 112, E1317-25	392
1833	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. 2015 , 47, 257-62	253
1832	Homologous-recombination-deficient tumours are dependent on PolE-mediated repair. <i>Nature</i> , 2015 , 518, 258-62	50.4 451
1831	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. 2015 , 25, 316-27	240
1830	Pancreatic cancer genomics: where can the science take us?. 2015 , 88, 213-9	10
1829	Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. 2015 , 112, 1107-12	112
1828	Prognostic significance of POLE proofreading mutations in endometrial cancer. 2015 , 107, 402	169
1827	The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. 2015 , 29, 677-85	104
1826	Novel recurrently mutated genes in African American colon cancers. 2015 , 112, 1149-54	77
1825	The theory of RNA-mediated gene evolution. 2015 , 10, 1-5	14
1824	Augmented pentose phosphate pathway plays critical roles in colorectal carcinomas. 2015 , 88, 309-19	19
1823	Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. 2015 , 27, 15-26	672

1822	Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. 2015 , 100, E360-4		68
1821	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015 , 518, 495-501	50.4	1579
1820	ImmTACs for targeted cancer therapy: Why, what, how, and which. 2015 , 67, 67-74		59
1819	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. 2015 , 107,		72
1818	Big Bang and context-driven collapse. 2015 , 47, 196-7		17
1817	Avalanching mutations in biallelic mismatch repair deficiency syndrome. 2015 , 47, 194-6		3
1816	APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. 2015 , 112, 2841-6		95
1815	[Biomaterial banks are crucial to developing genetically-based prevention concepts]. 2015 , 58, 127-30		0
1814	Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma. 2015 , 29, 1612-5		17
1813	Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. 2015 , 33, 120-5		44
1812	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. 2015 , 14, 847-56		1248
1811	Differential DNA mismatch repair underlies mutation rate variation across the human genome. <i>Nature</i> , 2015 , 521, 81-4	50.4	224
1810	Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. 2015 , 88, 9-15		14
1809	Therapeutic opportunities within the DNA damage response. 2015 , 15, 166-80		329
1808	Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. 2015 , 17, 15		22
1807	Translational implications of tumor heterogeneity. 2015 , 21, 1258-66		292
1806	The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. 2015 , 16, 225-38		889
1805	PIKING the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. 2015 , 137, 321-8		14

1804	Deciphering the genetic evolution of T-cell resistance in melanoma. 2015 , 4, e1005510	2
1803	Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. 2015 , 126, 508-19	142
1802	Mutational Similarities Across Cancers: Implications for Research, Diagnostics, and Personalized Therapy Design. 2015 , 57-65	
1801	High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma. 2015 , 33, 340.e1-8	27
1800	Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. 2015 , 149, 1142-1152.e3	22
1799	Origins, genetic landscape, and emerging therapies of small cell lung cancer. 2015 , 29, 1447-62	133
1798	Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. 2015 , 5, 11966	55
1797	A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. 2015 , 75, 3980-90	88
1796	Maximizing derivable information from cytologic specimens for pathologic and molecular diagnostics. 2015 , 4, 141-147	2
1795	What to expect from high throughput genomics in metastatic breast cancers?. 2015 , 24 Suppl 2, S19-22	3
1794	Evolutionary determinants of cancer. 2015 , 5, 806-20	242
1793	Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. 2015 , 16, 1149-60	11
1792	A New Era of Low-Dose Radiation Epidemiology. 2015 , 2, 236-49	17
1791	Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. 2015 , 5, 821-831	173
1790	Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer. 2015 , 112, E4571-80	53
1789	Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome. 2015 , 13, 1218-26	24
1788	Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. 2015 , 33, 3080-1	28
1787	TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. 2015 , 43, 6945-58	37

1786	Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer. 2015 , 17, 348-57	2
1785	Disruption of Transcriptional Coactivator Sub1 Leads to Genome-Wide Re-distribution of Clustered Mutations Induced by APOBEC in Active Yeast Genes. 2015 , 11, e1005217	37
1784	Genetic Intratumor Heterogeneity. 2015 , 571-593	1
1783	Personalized Therapy Epigenetic Profiling as Predictors of Prognosis and Response. 2015 , 677-698	1
1782	The genomic evolution of human prostate cancer. 2015 , 113, 193-8	39
1781	Oxidative Damage to RPA Limits the Nucleotide Excision Repair Capacity of Human Cells. 2015 , 135, 2834-2841	41
1780	Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. 2015 , 6, 7557	110
1779	Adoptive T-cell therapy: a need for standard immune monitoring. 2015 , 7, 513-33	16
1778	Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer. 2015 , 44, 625-38	14
1777	Analysis of intratumor heterogeneity unravels lung cancer evolution. 2015 , 2, e985549	22
1776	Integrating genomics in head and neck cancer treatment: Promises and pitfalls. 2015 , 95, 397-406	23
1775	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. 2015 , 21, 946-54	127
1774	Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. 2015 , 149, 1153-1162.e3	250
1773	Mutation-induced protein interaction kinetics changes affect apoptotic network dynamic properties and facilitate oncogenesis. 2015 , 112, E4046-54	27
1772	Handbook of Multiple Myeloma. 2015 ,	3
1771	Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. 2015 , 47, 1038-1046	190
1770	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. 2015 , 149, 1226-1239.e4	695
1769	Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability. 2015 , 43, 3667-79	34

1768	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015 , 526, 519-24	50.4	565
1767	Precision medicine for metastatic breast cancer—limitations and solutions. 2015 , 12, 693-704		201
1766	Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling. 2015 , 96, 274-307		7
1765	Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry. 2015 , 33, 101-10		25
1764	Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations. 2015 , 75, 3292-301		14
1763	Understanding next generation sequencing in oncology: A guide for oncologists. 2015 , 96, 463-74		28
1762	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. 2015 , 1, 486-94		27
1761	Network-based approaches for drug response prediction and targeted therapy development in cancer. 2015 , 464, 386-91		23
1760	Genomic heterogeneity in multiple myeloma. 2015 , 30, 56-65		26
1759	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. 2015 , 21, 482-91		109
1758	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. 2015 , 5, 704-12		267
1757	Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach. 2015 , 16, 13610-32		42
1756	Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. 2015 , 7, 1037-51		6
1755	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. 2015 , 373, 35-47		361
1754	Protein domain-level landscape of cancer-type-specific somatic mutations. 2015 , 11, e1004147		46
1753	Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. 2015 , 7, 655-67		76
1752	Mutational dynamics between primary and relapse neuroblastomas. 2015 , 47, 872-7		191
1751	Colon cancer-associated mutator DNA polymerase ϵ variant causes expansion of dNTP pools increasing its own infidelity. 2015 , 112, E2467-76		45

1750	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. 2015 , 6, 6997	176
1749	Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. 2015 , 96, 597-611	222
1748	Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer. 2015 , 208, 271-8	10
1747	37th Annual San Antonio Breast Cancer Symposium. Resumen de las aportaciones translacionales y clínicas más relevantes. 2015 , 28, 85-89	
1746	The future of immune checkpoint therapy. 2015 , 348, 56-61	2733
1745	Neoantigens in cancer immunotherapy. 2015 , 348, 69-74	2790
1744	Pembrolizumab for the treatment of non-small-cell lung cancer. 2015 , 372, 2018-28	3943
1743	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. 2015 , 11, 92-97	4
1742	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. 2015 , 7, 283ra54	417
1741	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. 2015 , 15, 647-64	32
1740	Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. 2015 , 17, 8	57
1739	Hypermutation takes the driver's seat. 2015 , 7, 31	14
1738	Molecular pathogenesis of multiple myeloma. 2015 , 20, 413-22	41
1737	Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. 2015 , 161, 1035-1045	170
1736	Genetic variations of human papillomavirus type 16: implications for cervical carcinogenesis. 2015 , 68, 169-75	12
1735	A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. 2015 , 26, 1180-1187	11
1734	Hepatic inflammation facilitates transcription-associated mutagenesis via AID activity and enhances liver tumorigenesis. 2015 , 36, 904-13	10
1733	Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. 2015 , 27, 712-27	55

1732	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. 2015 , 348, 124-8	5003
1731	The interplay of effector and regulatory T cells in cancer. 2015 , 33, 101-11	88
1730	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. 2015 , 6, 6336	85
1729	Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours. 2015 , 236, 186-200	11
1728	Next Generation Sequencing in Cancer Research, Volume 2. 2015 ,	4
1727	Dissecting genetic and environmental mutation signatures with model organisms. 2015 , 31, 465-74	14
1726	Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. 2015 , 348, 803-8	798
1725	Melanoma. 2015 , 1, 15003	283
1724	Racial diversity of actionable mutations in non-small cell lung cancer. 2015 , 10, 250-5	36
1723	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. 2015 , 47, 367-372	292
1722	Gene expression. MicroRNA control of protein expression noise. 2015 , 348, 128-32	252
1721	Translating genomic discoveries to the clinic in pediatric oncology. 2015 , 27, 34-43	26
1720	AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature. 2015 , 25, 60-71	48
1719	Evidence for recent, population-specific evolution of the human mutation rate. 2015 , 112, 3439-44	107
1718	APOBECs and virus restriction. 2015 , 479-480, 131-45	291
1717	How the environment shapes cancer genomes. 2015 , 27, 71-7	27
1716	Genomic rearrangements in prostate cancer. 2015 , 25, 71-6	23
1715	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. 2015 , 47, 505-511	956

1714	APOBEC3 genes: retroviral restriction factors to cancer drivers. 2015 , 21, 274-84	72
1713	Cancer whole-genome sequencing: present and future. 2015 , 34, 5943-50	71
1712	Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. 2015 , 75, 2264-71	31
1711	Decoding genomes. 2015 , 43, 1-5	1
1710	Sequencing small genomic targets with high efficiency and extreme accuracy. 2015 , 12, 423-5	95
1709	The journey from discoveries in fundamental immunology to cancer immunotherapy. 2015 , 27, 439-49	157
1708	Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. 2015 , 161, 205-14	1388
1707	The cancer which survived: insights from the genome of an 11000 year-old cancer. 2015 , 30, 49-55	37
1706	The first five years of single-cell cancer genomics and beyond. 2015 , 25, 1499-507	238
1705	Genetics and genomics of psychiatric disease. 2015 , 349, 1489-94	249
1704	The origins, determinants, and consequences of human mutations. 2015 , 349, 1478-83	111
1703	Somatic mutation in cancer and normal cells. 2015 , 349, 1483-9	608
1702	SomaticSignatures: inferring mutational signatures from single-nucleotide variants. 2015 , 31, 3673-5	174
1701	Subgraph augmented non-negative tensor factorization (SANTF) for modeling clinical narrative text. 2015 , 22, 1009-19	38
1700	"" vaccination for systemic effects in follicular lymphoma. 2015 , 4, e1014773	1
1699	Genomic approaches to DNA repair and mutagenesis. 2015 , 36, 146-155	20
1698	Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. 2015 , 112, 12492-7	36
1697	Harmful somatic amino acid substitutions affect key pathways in cancers. 2015 , 8, 53	12

1696	Personalizing the management of gastroesophageal cancer. 2015 , 12, 447-451	
1695	Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. 2015 , 195, 4028-37	18
1694	Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. 2015 , 21, 1514-20	75
1693	Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. 2015 , 24, 1873-81	16
1692	Discovery and functional characterization of a neomorphic PTEN mutation. 2015 , 112, 13976-81	31
1691	Crystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain. 2015 , 290, 28120-28130	71
1690	Comparison against 186 canid whole-genome sequences reveals survival strategies of an ancient clonally transmissible canine tumor. 2015 , 25, 1646-55	48
1689	The Molecular Taxonomy of Primary Prostate Cancer. 2015 , 163, 1011-25	1713
1688	The emerging role of lncRNAs in cancer. 2015 , 21, 1253-61	1711
1687	Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. 2015 , 3, 9	116
1686	Next-generation sequencing and empowering personalised cancer medicine. 2015 , 20, 1470-5	20
1685	The PKC/NF- κ B signaling pathway induces APOBEC3B expression in multiple human cancers. 2015 , 75, 4538-47	87
1684	The Diverse Effects of Complex Chromosome Rearrangements and Chromothripsis in Cancer Development. 2015 , 200, 165-93	9
1683	Functional and genetic deconstruction of the cellular origin in liver cancer. 2015 , 15, 653-67	190
1682	The path to routine use of genomic biomarkers in the cancer clinic. 2015 , 25, 1508-13	26
1681	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. 2015 , 1, 197-209	72
1680	Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. 2015 , 9, 1918-35	74
1679	Big Data: the challenge for small research groups in the era of cancer genomics. 2015 , 113, 1405-12	34

1678	A mutational signature in gastric cancer suggests therapeutic strategies. 2015 , 6, 8683	103
1677	Genomic spectra of biliary tract cancer. 2015 , 47, 1003-10	612
1676	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. 2015 , 47, 1067-72	238
1675	Mutation signatures implicate aristolochic acid in bladder cancer development. 2015 , 7, 38	63
1674	Extensive de novo mutation rate variation between individuals and across the genome of <i>Chlamydomonas reinhardtii</i> . 2015 , 25, 1739-49	66
1673	Rolling the Genetic Dice: Neutral and Deleterious Smoothed Mutations in Drug-Resistant Basal Cell Carcinoma. 2015 , 135, 2138-2141	17
1672	Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. 2015 , 28, 1383-9	35
1671	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. 2015 , 13, 277-89	137
1670	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. 2015 , 41, 914-24	33
1669	Genomic landscape of adenoid cystic carcinoma of the breast. 2015 , 237, 179-89	101
1668	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. 2015 , 13, 108-121	64
1667	Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. 2015 , 113, 864-71	45
1666	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. 2015 , 5, 1137-54	436
1665	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. 2015 , 32, 821-34	10
1664	T cells in cancer. 2015 , 15, 683-91	320
1663	The genome as a record of environmental exposure. 2015 , 30, 763-70	115
1662	Congrès de l'association américaine de recherche contre le cancer (AACR) 2015. 2015 , 17, 277-298	
1661	Mutations driving CLL and their evolution in progression and relapse. <i>Nature</i> , 2015 , 526, 525-30	50.4 658

1660	Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. 2015 , 33, 1165-72	551
1659	Chromothripsis: A New Mechanism for Rapid Karyotype Evolution. 2015 , 49, 183-211	122
1658	LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations. 2015 , 43, 8123-34	48
1657	Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. 2015 , 16, 1000-7	6
1656	Cancer Genetics and Implications for Clinical Management. 2015 , 95, 919-34	5
1655	Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. 2015 , 2, 291-302	5
1654	Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. 2015 , 17, 554-9	49
1653	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. 2015 , 11, 2790-5	43
1652	Next-generation sequencing: hype and hope for development of personalized radiation therapy?. 2015 , 10, 183	8
1651	Spatiotemporal Evolution of the Primary Glioblastoma Genome. 2015 , 28, 318-28	180
1650	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. 2015 , 47, 1194-9	177
1649	The molecular landscape of premenopausal breast cancer. 2015 , 17, 104	38
1648	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. 2015 , 47, 1168-78	893
1647	Hereditary Pancreatic Cancer Syndromes. 2015 , 24, 733-64	23
1646	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. 2015 , 75, 3720-3727	196
1645	[Nivolumab, a new hope in non-small cell lung cancer]. 2015 , 102, 1046-52	2
1644	The emergence of immuno-oncology companion products. 2015 , 12, 435-438	3
1643	Current state of biomarkers in ovarian cancer prognosis. 2015 , 11, 3187-95	36

1642	The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues. 2015 , 208, 415-27	30
1641	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. 2015 , 30, 1-6	52
1640	Characterization of the Catalytic Domain of Human APOBEC3B and the Critical Structural Role for a Conserved Methionine. 2015 , 427, 3042-55	24
1639	Clock-like mutational processes in human somatic cells. 2015 , 47, 1402-7	531
1638	Genomic profiling of S _H ary syndrome identifies alterations of key T cell signaling and differentiation genes. 2015 , 47, 1426-34	199
1637	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. 2015 , 9, 2054-62	60
1636	Using common variants to indicate cancer genes. 2015 , 136, 241-5	
1635	Solexa sequencing: decoding genomes on a population scale. 2015 , 61, 21-4	17
1634	Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation. 2015 , 31, 84-93	5
1633	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. 2015 , 21, 81-5	478
1632	Both high-fidelity replicative and low-fidelity Y-family polymerases are involved in DNA rereplication. 2015 , 35, 699-715	13
1631	APOBEC3A catabolism of electroporated plasmid DNA in mouse muscle. 2015 , 22, 96-103	5
1630	SF3B1 mutations constitute a novel therapeutic target in breast cancer. 2015 , 235, 571-80	124
1629	Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. 2015 , 136, 2967-72	27
1628	The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. 2015 , 36, 118-28	28
1627	Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. 2015 , 30, 4-12	176
1626	Driver and passenger mutations in cancer. 2015 , 10, 25-50	179
1625	The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. <i>Nature</i> , 2015 , 517, 489-92	50.4 223

1624	Beyond BRAF: where next for melanoma therapy?. 2015 , 112, 217-26	87
1623	The history, genotoxicity, and carcinogenicity of carbon-based fuels and their emissions: part 5. Summary, comparisons, and conclusions. 2015 , 763, 103-47	18
1622	APOBEC3A functions as a restriction factor of human papillomavirus. 2015 , 89, 688-702	113
1621	Wip1 phosphatase in breast cancer. 2015 , 34, 4429-38	34
1620	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. 2015 , 34, 3215-25	94
1619	Do age-associated DNA methylation changes increase the risk of malignant transformation?. 2015 , 37, 20-4	20
1618	Novel points of attack for targeted cancer therapy. 2015 , 116, 9-18	34
1617	Genomic and epigenomic co-evolution in follicular lymphomas. 2015 , 29, 456-63	48
1616	EZH2: an emerging role in melanoma biology and strategies for targeted therapy. 2015 , 28, 21-30	38
1615	Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations. 2016 , 7, 40491-40499	24
1614	1. Classification of lymphomas Past, present and future. 2016 , 1-12	
1613	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. 2016 , 7, 69450-69465	42
1612	Neoantigen-based cancer immunotherapy. 2016 , 4, 262	55
1611	Checkpoint Inhibitors for Advanced Bladder Cancer. 2016 , 2, 473-474	1
1610	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. 2016 , 11, 87-92	1
1609	Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. 2016 , 7, 22857-64	42
1608	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. 2016 , 17,	16
1607	What is the Current Role of Immunotherapy for Colon Cancer?. 2016 , 11, 93-8	3

1606	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17	18
1605	High-specificity detection of rare alleles with Paired-End Low Error Sequencing (PELE-Seq). 2016 , 17, 464	11
1604	Immunological battlefield in gastric cancer and role of immunotherapies. 2016 , 22, 6373-84	22
1603	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. 2016 , 7, 771-788	61
1602	Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. 2016 , 35, e141-9	41
1601	The head and neck cancer immune landscape and its immunotherapeutic implications. 2016 , 1, e89829	356
1600	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. 2016 , 7, 3403-15	229
1599	Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. 2016 , 35, e442-8	6
1598	CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. 2016 , 126, 2610-20	220
1597	Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. 2016 , 35, e259-68	10
1596	Emerging strategies for the treatment of advanced small cell lung cancer. 2016 , 8, E1249-E1253	1
1595	Genomic landscape of DNA repair genes in cancer. 2016 , 7, 23312-21	101
1594	DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations. 2016 , 7, 64289-64299	37
1593	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. 2016 , 24, 7	3
1592	Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis. 2016 , 23, e49-56	5
1591	Abnormal Expressions of DNA Glycosylase Genes NEIL1, NEIL2, and NEIL3 Are Associated with Somatic Mutation Loads in Human Cancer. 2016 , 2016, 1546392	24
1590	Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. 2016 , 7, 60807-60822	16
1589	Networks and Consortia for Epigenetic Drug Discovery. 2016 , 143-166	1

1588	Clinical utility of nivolumab in the treatment of advanced melanoma. 2016 , 12, 313-25	12
1587	Mitochondrial genetic diversity, selection and recombination in a canine transmissible cancer. 2016 , 5,	37
1586	Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. 2016 , 7, 345	50
1585	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. 2016 , 7, 610	87
1584	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. 2016 , 7, 621	90
1583	Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. 2016 , 6, 139	15
1582	Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. 2016 , 6, 141	88
1581	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. 2016 , 6, 256	28
1580	Cancer Vaccines in Ovarian Cancer: How Can We Improve?. 2016 , 4,	38
1579	Targeting DNA Replication Stress for Cancer Therapy. 2016 , 7,	47
1578	DNA Damage and Repair in Schizophrenia and Autism: Implications for Cancer Comorbidity and Beyond. 2016 , 17,	36
1577	Signaling Pathways in Melanogenesis. 2016 , 17,	346
1576	A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer. 2016 , 16, 529	4
1575	Immunohistochemical detection of inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma. 2016 , 101, e259-61	1
1574	Identifying Network Perturbation in Cancer. 2016 , 12, e1004888	26
1573	Quantitative Trait Loci Identify Functional Noncoding Variation in Cancer. 2016 , 12, e1005826	5
1572	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. 2016 , 13, e1002136	25
1571	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. 2016 , 13, e1002201	214

1570	Mutational Profiles Reveal an Aberrant TGF- β -ECEA Regulated Pathway in Colon Adenomas. 2016 , 11, e0153933	13
1569	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. 2016 , 11, e0155189	77
1568	Origin of B-Cell Neoplasms in Autoimmune Disease. 2016 , 11, e0158360	13
1567	PD-L1 expression in human cancers and its association with clinical outcomes. 2016 , 9, 5023-39	370
1566	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. 2016 , 11, e0161731	11
1565	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. 2016 , 1,	22
1564	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. 2016 , 22, 101-7	17
1563	Immune Checkpoint Therapy in Head and Neck Cancers. 2016 , 22, 108-16	10
1562	Distinct genetic profiles of extracranial and intracranial acral melanoma metastases. 2016 , 43, 884-91	2
1561	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. 2016 , 55, 251-67	62
1560	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. 2016 , 22, 4309-21	127
1559	Functional annotation of noncoding variants and prioritization of cancer-associated lncRNAs in lung cancer. 2016 , 12, 222-230	8
1558	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. 2016 , 129, 453-460	61
1557	Ontogenic growth as the root of fundamental differences between childhood and adult cancer. 2016 , 34, 543-50	6
1556	Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels. 2016 , 16, 672-83	19
1555	Genetic and epigenetic determinants of B-cell lymphoma evolution. 2016 , 23, 392-401	3
1554	Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. 2016 , 2, e70	19
1553	Hedera nepalensis K. Koch: A Novel Source of Natural Cancer Chemopreventive and Anticancerous Compounds. 2016 , 30, 447-53	10

1552	mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome. 2016 , 37, 447-56	51
1551	TERT promoter mutations in melanoma survival. 2016 , 139, 75-84	79
1550	Update on immune therapy in melanoma. 2016 , 4, 799-808	
1549	Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. 2016 , 50, 286-94	36
1548	Molecular landscapes of human hematopoietic stem cells in health and leukemia. 2016 , 1370, 5-14	21
1547	New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. 2016 , 22, 4283-90	26
1546	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. 2016 , 101, 794-802	62
1545	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. 2016 , 113, 7944-5	6
1544	Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/ β -catenin signaling pathway mutations. 2016 , 122, 1689-96	17
1543	New paradigms in clonal evolution: punctuated equilibrium in cancer. 2016 , 240, 126-36	54
1542	Characterization of MHC Class I and β 2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials. 2016 , 63, 618-26	10
1541	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. 2016 , 18, 1357-66	97
1540	Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. 2016 , 122, 367-77	96
1539	Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. 2016 , 46, 1351-60	23
1538	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. 2016 , 55, 626-39	63
1537	Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. 2016 , 270, 178-92	24
1536	Immunotherapy for uveal melanoma. 2016 , 3, 125-135	3
1535	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. 2016 , 14, 1213-1224	73

1534	Fragile Genes That Are Frequently Altered in Cancer: Players Not Passengers. 2016 , 150, 208-216	26
1533	Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia. 2016 , 47, 677-683	3
1532	Chromosome Imbalances in Cancer: Molecular Cytogenetics Meets Genomics. 2016 , 150, 176-184	10
1531	New insights into the generation and role of de novo mutations in health and disease. 2016 , 17, 241	215
1530	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. 2016 , 1,	74
1529	Activation induced deaminase mutational signature overlaps with CpG methylation sites in follicular lymphoma and other cancers. 2016 , 6, 38133	18
1528	Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. 2016 , 1, e000094	102
1527	Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection. 2016 , 6, 21927	9
1526	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. 2016 , 17 Suppl 2, 394	21
1525	Cell type-specific properties and environment shape tissue specificity of cancer genes. 2016 , 6, 20707	50
1524	The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. 2016 , 8, 442-57	154
1523	Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. 2016 , 7, 11588	19
1522	A cloud-based workflow to quantify transcript-expression levels in public cancer compendia. 2016 , 6, 39259	48
1521	Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. 2016 , 7, 12157	58
1520	Divergent viral presentation among human tumors and adjacent normal tissues. 2016 , 6, 28294	44
1519	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. 2016 , 4, 95	13
1518	MGUS to myeloma: a mysterious gammopathy of underexplored significance. 2016 , 128, 2599-2606	83
1517	Germline MC1R status influences somatic mutation burden in melanoma. 2016 , 7, 12064	75

1516	The SCAR (Scar Cosmesis Assessment and Rating) scale: new evaluation method for postoperative scars. 2016 , 175, 1151-1152	4
1515	Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise. 2016 , 175, 1150-1151	7
1514	iCAGES: integrated CAnceR GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes. 2016 , 8, 135	31
1513	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. 2016 , 8, 133	95
1512	Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. 2016 , 7, 12601	88
1511	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in -associated and sporadic triple-negative breast cancer. 2016 , 2, 16002	22
1510	CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia. 2016 , 101, 1534-1543	16
1509	A proteogenomic approach for protein-level evidence of genomic variants in cancer cells. 2016 , 6, 35305	9
1508	Emerging therapeutic agents for lung cancer. 2016 , 9, 138	65
1507	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. 2016 , 2, a001263	13
1506	Functional Mutations Form at CTCF-Cohesin Binding Sites in Melanoma Due to Uneven Nucleotide Excision Repair across the Motif. 2016 , 17, 2865-2872	39
1505	Distinctive features of single nucleotide alterations in induced pluripotent stem cells with different types of DNA repair deficiency disorders. 2016 , 6, 26342	6
1504	Merkel Cell Carcinoma: Characteristics, Management, and What's on the Horizon. 2016 , 1, 66-74	1
1503	Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. 2016 , 22, 190-5	18
1502	Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines. 2016 , 10, 116	7
1501	Immune based prognostic biomarkers for multiple anticancer therapies in lung adenocarcinoma. 2016 ,	
1500	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 2016 , 6, 19552	20
1499	Mutation induction in the mouse and human germline. 2016 , 52, 17-28	2

1498	Next generation sequencing: implications in personalized medicine and pharmacogenomics. 2016 , 12, 1818-30	63
1497	Signatures of Mutational Processes and Associated Risk Factors in Esophageal Squamous Cell Carcinoma: A Geographically Independent Stratification Strategy?. 2016 , 150, 1080-1083	3
1496	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. 2016 , 4, 463-71	59
1495	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. 2016 , 8, 681-6	1
1494	Novel immunotherapies for the treatment of melanoma. 2016 , 8, 613-32	5
1493	CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. 2016 , 197, 179-87	37
1492	Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells. 2016 , 76, 4569-78	12
1491	Genomic Landscape of Colorectal Mucosa and Adenomas. 2016 , 9, 417-27	58
1490	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. 2016 , 65, 753-63	25
1489	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. 2016 , 48, 758-67	209
1488	Elevated variant density around SV breakpoints in germline lineage lends support to error-prone replication hypothesis. 2016 , 26, 874-81	3
1487	Targeting PD-L1 for non-small-cell lung cancer. 2016 , 8, 747-58	10
1486	Personalised Treatment in Gastric Cancer: Myth or Reality?. 2016 , 18, 41	11
1485	Carcinogen-specific mutations in preferred Ras-Raf pathway oncogenes directed by strand bias. 2016 , 37, 810-816	6
1484	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. 2016 , 22, 3132-7	22
1483	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. 2016 , 11, 313-41	12
1482	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504	280
1481	Understanding mutagenesis through delineation of mutational signatures in human cancer. 2016 , 37, 531-40	66

1480	Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress. 2016 , 31, 573-82	8
1479	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. 2016 , 24, 1323-32	19
1478	3-methylcytosine in cancer: an underappreciated methyl lesion?. 2016 , 8, 451-4	10
1477	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. 2016 , 38, 1622-35	13
1476	The Complete Genome Sequences, Unique Mutational Spectra, and Developmental Potency of Adult Neurons Revealed by Cloning. 2016 , 89, 1223-1236	69
1475	Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. 2016 , 25, 1875-84	70
1474	Clustered mutations in hominid genome evolution are consistent with APOBEC3G enzymatic activity. 2016 , 26, 579-87	11
1473	Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes. <i>Nature</i> , 2016 , 532, 259-63	50.4 138
1472	Nucleotide excision repair is impaired by binding of transcription factors to DNA. <i>Nature</i> , 2016 , 532, 264-70.4	192
1471	Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors. 2016 , 98, 818-829	26
1470	The role of neoantigens in response to immune checkpoint blockade. 2016 , 28, 411-9	88
1469	Genetic Testing for Rare Cancer: The Wider Issues. 2016 , 205, 213-26	1
1468	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. 2016 , 29, 735-42	43
1467	Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. 2016 , 22, 1897-906	217
1466	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. 2016 , 22, 1865-74	421
1465	Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors. 2016 , 376, 347-59	15
1464	Rapid and dynamic transcriptome regulation by RNA editing and RNA modifications. 2016 , 213, 15-22	75
1463	Nucleosome positioning changes during human embryonic stem cell differentiation. 2016 , 11, 426-37	7

1462	Immune checkpoint inhibition in ovarian cancer. 2016 , 28, 339-48	96
1461	Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. 2016 , 57, 73-85	8
1460	Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. 2016 , 12, 1439-56	47
1459	Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. 2016 , 48, 500-9	423
1458	Investigational drugs for head and neck cancer. 2016 , 25, 797-810	11
1457	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. 2016 , 113, 6005-10	104
1456	WeSME: uncovering mutual exclusivity of cancer drivers and beyond. 2017 , 33, 814-821	41
1455	Cancer immunotherapy: the beginning of the end of cancer?. 2016 , 14, 73	651
1454	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. 2016 , 29, 723-736	324
1453	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. 2016 , 48, 607-16	613
1452	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-54	1193
1451	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. 2016 , 22, 632-40	122
1450	Coupling end resection with the checkpoint response at DNA double-strand breaks. 2016 , 73, 3655-63	26
1449	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. 2016 , 48, 600-606	238
1448	Oxidative Stress-Induced Protein Damage Inhibits DNA Repair and Determines Mutation Risk and Therapeutic Efficacy. 2016 , 14, 612-22	52
1447	Biomarkers associated with checkpoint inhibitors. 2016 , 27, 1199-206	112
1446	International cancer seminars: a focus on kidney cancer. 2016 , 27, 1382-5	11
1445	Upgrading biomaterials with synthetic biological modules for advanced medical applications. 2016 , 105, 77-95	19

1444	Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. 2016 , 196, 4793-804	6
1443	The role of the RAS pathway in iAMP21-ALL. 2016 , 30, 1824-31	28
1442	Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. 2016 , 29, 622-637	160
1441	Nuclear Magnetic Resonance Structure of the APOBEC3B Catalytic Domain: Structural Basis for Substrate Binding and DNA Deaminase Activity. 2016 , 55, 2944-59	41
1440	Roles for retrotransposon insertions in human disease. 2016 , 7, 9	333
1439	The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. 2016 , 12, 1833-46	13
1438	Optimizing T-cell receptor gene therapy for hematologic malignancies. 2016 , 127, 3305-11	52
1437	Clonal hematopoiesis in acquired aplastic anemia. 2016 , 128, 337-47	101
1436	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. 2016 , 64, 587-600	24
1435	Chemically-Induced Hepatocarcinogenesis. 2016 , 65-92	
1434	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. 2016 , 48, 1131-41	233
1433	Classical NF- κ B pathway is responsible for APOBEC3B expression in cancer cells. 2016 , 478, 1466-71	40
1432	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. 2016 , 6, 1258-1266	48
1431	Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes. 2016 , 65, 1377-1393	33
1430	Factor models for cancer signatures. 2016 , 462, 527-559	3
1429	[The new challenge in oncology: Next-generation sequencing and its application in precision medicine]. 2016 , 85, 273.e1-273.e7	4
1428	Difference Makers: Chromosomal Instability versus Aneuploidy in Cancer. 2016 , 2, 561-571	31
1427	Immunotherapy of Melanoma. 2016 , 39, 369-76	10

1426	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. 2016 , 6, 1230-1236	196
1425	The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process. 2016 , 50, 347-369	57
1424	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. 2016 , 22, 5651-5660	91
1423	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. 2016 , 67, 130-140	12
1422	Tissue-specific mutation accumulation in human adult stem cells during life. <i>Nature</i> , 2016 , 538, 260-264	50.4 523
1421	Precision medicine from the renal cancer genome. 2016 , 12, 655-666	37
1420	DNA replication stress: a source of APOBEC3B expression in breast cancer. 2016 , 17, 202	14
1419	The genomic landscape of breast cancer and its interaction with host immunity. 2016 , 29, 241-50	130
1418	Rekindling cancer vaccines. 2016 , 34, 1019-1024	31
1417	Molecular Genetics of Pancreatic Neoplasms. 2016 , 9, 685-703	9
1416	A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. <i>Nature</i> , 2016 , 538, 378-382	50.4 304
1415	Importance of rare gene copy number alterations for personalized tumor characterization and survival analysis. 2016 , 17, 204	14
1414	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. 2016 , 1, 207-216	160
1413	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. 2016 , 22, 5642-5650	98
1412	Rev1 is a base excision repair enzyme with 5'-deoxyribose phosphate lyase activity. 2016 , 44, 10824-10833	12
1411	Chromatin structure-based prediction of recurrent noncoding mutations in cancer. 2016 , 48, 1321-1326	21
1410	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. 2016 , 5, e1240859	51
1409	Elementary: breast cancer culprits leave their signatures on the double helix. 2016 , 23, 1577-8	

1408	Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes. 2016 , 37, 817-826	46
1407	Genomic insights into head and neck cancer. 2016 , 1,	51
1406	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. 2016 , 6,	82
1405	TRIC: an automated alignment strategy for reproducible protein quantification in targeted proteomics. 2016 , 13, 777-83	122
1404	Is Mutation Random or Targeted?: No Evidence for Hypermutability in Snail Toxin Genes. 2016 , 33, 2642-7	3
1403	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. 2016 , 76, 5894-5906	65
1402	Targeting deficient DNA damage repair in gastric cancer. 2016 , 17, 1757-66	10
1401	The metabolomic signature of hematologic malignancies. 2016 , 49, 22-35	14
1400	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. 2016 , 45, 389-401	318
1399	Clinical Outcomes of TP53 Mutations in Cancers. 2016 , 6,	35
1398	Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. 2016 , 2, 166-74	9
1397	Socializing Individualized T-Cell Cancer Immunotherapy. 2016 , 24, 1170-3	1
1396	Somatic TP53 Mutations in the Era of Genome Sequencing. 2016 , 6,	115
1395	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. 2016 , 6,	204
1394	Dual Chromatin and Cytoskeletal Remodeling by SETD2. 2016 , 166, 950-962	128
1393	Somatic hypermutation in immunity and cancer: Critical analysis of strand-biased and codon-context mutation signatures. 2016 , 45, 1-24	15
1392	Patient-derived tumor xenograft models for melanoma drug discovery. 2016 , 11, 895-906	14
1391	The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study. 2016 , 2, 9-20	17

1390	The genomic landscape of cutaneous melanoma. 2016 , 29, 266-83	100
1389	Immunotherapy for lung cancer. 2016 , 21, 821-33	126
1388	Translating cancer genomes and transcriptomes for precision oncology. 2016 , 66, 75-88	108
1387	Chronic lymphocytic leukemia: Time to go past genomics?. 2016 , 91, 518-28	11
1386	Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse. 2016 , 107, 528-35	13
1385	Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. 2016 , 9, 148-160	44
1384	Sequencing Structural Variants in Cancer for Precision Therapeutics. 2016 , 32, 530-542	55
1383	Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. 2016 , 48, 1260-6	53
1382	Global genome nucleotide excision repair is organized into domains that promote efficient DNA repair in chromatin. 2016 , 26, 1376-1387	20
1381	Studying Cancer Evolution in Barrett's Esophagus and Esophageal Adenocarcinoma. 2016 , 908, 213-36	1
1380	Genomics Study of Gastric Cancer and Its Molecular Subtypes. 2016 , 908, 419-39	9
1379	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. 2016 , 4, 820-822	44
1378	Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases. 2016 , 116, 12688-12710	70
1377	Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C. 2016 , 90, 10193-10208	11
1376	Long telomeres and cancer risk among 95 568 individuals from the general population. 2016 , 45, 1634-1643	62
1375	Energy parasites trigger oncogene mutation. 2016 , 92, 577-82	4
1374	Deep Genetic Connection Between Cancer and Developmental Disorders. 2016 , 37, 1042-50	10
1373	Intrinsic Versus Extrinsic Cancer Risk Factors and Aging. 2016 , 22, 833-834	14

1372	Aristolochic Acid in the Etiology of Renal Cell Carcinoma. 2016 , 25, 1600-1608	46
1371	Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. 2016 ,	3
1370	Cancer Cell Death-Inducing Radiotherapy: Impact on Local Tumour Control, Tumour Cell Proliferation and Induction of Systemic Anti-tumour Immunity. 2016 , 930, 151-72	8
1369	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. 2016 , 8, 314-36	6
1368	Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors. 2016 , 9, 405-26	11
1367	A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma. 2016 , 25, 1511-1516	13
1366	Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!. 2016 , 122, 3263-3266	2
1365	Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. 2016 , 115, 403-10	36
1364	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. 2016 , 76, 5954-5961	12
1363	Immunotherapy in Lung Cancer. 2016 , 170, 203-23	6
1362	Frontiers in Cancer Research. 2016 ,	
1361	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. 2016 , 34, 538-547	28
1360	Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. 2016 , 7, 13404	386
1359	Accurate, Direct, and High-Throughput Analyses of a Broad Spectrum of Endogenously Generated DNA Base Modifications with Isotope-Dilution Two-Dimensional Ultraperformance Liquid Chromatography with Tandem Mass Spectrometry: Possible Clinical Implication. 2016 , 88, 12128-12136	38
1358	Six Germline Genetic Variations Impair the Translesion Synthesis Activity of Human DNA Polymerase η . 2016 , 29, 1741-1754	6
1357	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. 2016 , 167, 260-274.e22	274
1356	Molecular Evolution Patterns in Metastatic Lymph Nodes Reflect the Differential Treatment Response of Advanced Primary Lung Cancer. 2016 , 76, 6568-6576	11
1355	[The clonal evolution of osteosarcomas]. 2016 , 37, 163-168	

1354	A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. 2016 , 2, a000992	11
1353	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. 2016 , 17, 185	96
1352	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. 2016 , 48, 1330-1338	104
1351	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. 2016 , 113, 11283-11288	107
1350	Application of glycoscience to the early detection of pancreatic cancer. 2016 , 107, 1357-1362	19
1349	The genetics of nodal marginal zone lymphoma. 2016 , 128, 1362-73	88
1348	Candidate driver genes involved in genome maintenance and DNA repair in Sjögren syndrome. 2016 , 127, 3387-97	71
1347	Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future. 2016 , 5, e1214791	1
1346	Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. 2016 , 6,	99
1345	Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. 2016 , 37, 843-857	9
1344	Interplay of genetic and epigenetic alterations in hepatocellular carcinoma. 2016 , 8, 993-1005	28
1343	Personalized Immunotherapy Targeting the Cancer Mutanome. 2016 , 426-433	1
1342	Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. 2016 , 237, 101-14	27
1341	Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. 2016 , 5, 511-23	35
1340	Immunotherapy for head and neck squamous cell carcinoma. 2016 , 9, 66-69	20
1339	Overestimating the Role of Environment in Cancers. 2016 , 9, 773-776	10
1338	Reactive Oxygen Species Dictate the Apoptotic Response of Melanoma Cells to TH588. 2016 , 136, 2277-2286	29
1337	Essential Roles for Polymerase δ -Mediated End Joining in the Repair of Chromosome Breaks. 2016 , 63, 662-673	135

1336	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. 2016 , 101, 3526-38	46
1335	Immunotherapy for oesophagogastric cancer. 2016 , 16, 1197-207	6
1334	Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. 2016 , 99, 1190-1198	99
1333	The tumour suppressor CYLD regulates the p53 DNA damage response. 2016 , 7, 12508	25
1332	Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. 2016 , 48, 1500-1507	139
1331	Clonal evolution of chemotherapy-resistant urothelial carcinoma. 2016 , 48, 1490-1499	161
1330	A somatic reference standard for cancer genome sequencing. 2016 , 6, 24607	39
1329	An Overview of Molecular Cancer Pathogenesis, Prognosis, and Diagnosis. 2016 , 1-26	4
1328	KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. 2016 , 1, e000076	14
1327	The pleiotropic role of non-coding genes in development and cancer. 2016 , 43, 104-113	17
1326	The mutational signature of chronic lymphocytic leukemia. 2016 , 473, 3725-3740	3
1325	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. 2016 , 7, 10767	140
1324	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. 2016 , 6, 27702	38
1323	Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. 2016 , 34, 556-565	16
1322	Making urothelial carcinomas less immune to immunotherapy. 2016 , 34, 534-537	1
1321	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. 2016 , 7, 11111	54
1320	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. 2016 , 8, 328rv4	1281
1319	Prioritization of non-coding disease-causing variants and long non-coding RNAs in liver cancer. 2016 , 12, 3987-3994	8

1318	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. 2016 , 4, 68	20
1317	Big Data Analytics in Genomics. 2016 ,	4
1316	Emerging role of checkpoint inhibition in localized bladder cancer. 2016 , 34, 548-555	14
1315	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. 2016 , 14, 168	87
1314	Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes. 2016 , 113-119	
1313	The topography of mutational processes in breast cancer genomes. 2016 , 7, 11383	172
1312	The new challenge in oncology: Next-generation sequencing and its application in precision medicine. 2016 , 85, 273.e1-273.e7	
1311	SSA-ME Detection of cancer driver genes using mutual exclusivity by small subnetwork analysis. 2016 , 6, 36257	9
1310	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. 2016 , 6, e472	32
1309	At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. 2016 , 100, 1255-1264	6
1308	Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer. 2016 , 8, 55	31
1307	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. 2016 , 7, 12910	74
1306	Pancreatic cancer. 2016 , 2, 16022	838
1305	Putative RNA-directed adaptive mutations in cancer evolution. 2016 , 7, 164-187	5
1304	Mutational signatures of ionizing radiation in second malignancies. 2016 , 7, 12605	152
1303	The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. 2016 , 7, 12918	107
1302	Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. 2016 , 7, ncomms11845	29
1301	Genomic heterogeneity of multiple synchronous lung cancer. 2016 , 7, 13200	85

1300	Perspectives of Machine Learning Techniques in Big Data Mining of Cancer. 2016 , 317-336	
1299	The genomic landscape of core-binding factor acute myeloid leukemias. 2016 , 48, 1551-1556	147
1298	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. 2016 , 2, e1601737	118
1297	Systemic Therapy for Metastatic Colorectal Cancer. 2016 , 275-338	
1296	Engineering and optimising deaminase fusions for genome editing. 2016 , 7, 13330	46
1295	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. 2016 , 375, 1767-1778	661
1294	Mutational signatures associated with tobacco smoking in human cancer. 2016 , 354, 618-622	562
1293	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. 2016 , 6, 1210-1211	10
1292	Chemoprevention in African American Men With Prostate Cancer. 2016 , 23, 415-423	4
1291	Review of the British Thoracic Society Winter Meeting 2015, 2-4 December, London, UK. 2016 , 71, 555-9	
1290	NLR5, a promising new entry in tumor immunology. 2016 , 4, 39	14
1289	Internationales Krebsgenomkonsortium (ICGC). 2016 , 28, 416-423	
1288	Predicting the recurrence of noncoding regulatory mutations in cancer. 2016 , 17, 492	5
1287	Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. 2016 , 18, 56	30
1286	Negative selection maintains transcription factor binding motifs in human cancer. 2016 , 17 Suppl 2, 395	11
1285	Emergence of heterogeneity in acute leukemias. 2016 , 11, 51	21
1284	How the future of clinical cancer diagnostics can contribute to overcoming race-associated cancer disparities. 2016 , 16, 1233-1235	1
1283	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. 2016 , 95, e5447	12

1282	High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. 2016 , 16, 1570-80	47
1281	Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution. 2016 , 139, 1546-56	15
1280	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. 2016 , 76, 4765-74	70
1279	APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. 2016 , 14, 1273-1282	118
1278	Harnessing the immune system in acute myeloid leukaemia. 2016 , 103, 62-77	61
1277	Immunotherapy in Breast Cancer. 2016 , 39, 335-45	11
1276	MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes. 2016 , 17, 170	36
1275	Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. 2016 , 16, 27	22
1274	High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations. 2016 , 18, 18	9
1273	Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. 2016 , 4, 17	116
1272	Advancements in Next-Generation Sequencing. 2016 , 17, 95-115	305
1271	Clonal evolution of glioblastoma under therapy. 2016 , 48, 768-76	390
1270	A new statistical method for curve group analysis of longitudinal gene expression data illustrated for breast cancer in the NOWAC postgenome cohort as a proof of principle. 2016 , 16, 28	14
1269	MSH2 Dysregulation Is Triggered by Proinflammatory Cytokine Stimulation and Is Associated with Liver Cancer Development. 2016 , 76, 4383-93	15
1268	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. 2016 , 4, 669-78	85
1267	Parent-of-origin-specific signatures of de novo mutations. 2016 , 48, 935-9	174
1266	Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. 2016 , 113, E3892-900	76
1265	Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases. 2016 , 108,	29

1264 Recent results of immunotherapy and perspectives for advanced NSCLC. **2016**, 5, 57-60

1263 Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. **2016**, 30, 27-42 325

1262 Defining chromosomal translocation risks in cancer. **2016**, 113, E3649-56 9

1261 Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. **2016**, 14, 589-98 20

1260 Long noncoding RNAs in cancer: mechanisms of action and technological advancements. **2016**, 15, 43 308

1259 Protein oxidation, UVA and human DNA repair. **2016**, 44, 178-185 77

1258 CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma. **2016**, 76, 4720-4727 34

1257 Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. **2016**, 11, 1819-1836 22

1256 Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. **2016**, 11, 1879-1890 118

1255 Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. **2016**, 34, 574-9 17

1254 Molecular pathogenesis of pancreatic ductal adenocarcinoma. **2016**, 22, 226-235 1

1253 Development and clinical application of an integrative genomic approach to personalized cancer therapy. **2016**, 8, 62 58

1252 Translational and clinical implications of the genetic landscape of prostate cancer. **2016**, 13, 597-610 45

1251 Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. **2016**, 12, 911-22 41

1250 Genetic profiling of hepatocellular carcinoma using next-generation sequencing. **2016**, 65, 1031-1042 156

1249 When Genome Maintenance Goes Badly Awry. **2016**, 62, 777-87 51

1248 Mutational signature of aristolochic acid: Clue to the recognition of a global disease. **2016**, 44, 205-211 36

1247 Activation-Induced Cytidine Deaminase Links Ovulation-Induced Inflammation and Serous Carcinogenesis. **2016**, 18, 90-9 17

1246	Toward precision medicine of breast cancer. 2016 , 13, 7	37
1245	DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. 2016 , 17, 31	571
1244	A comprehensive survey of the mutagenic impact of common cancer cytotoxics. 2016 , 17, 99	117
1243	Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer. 2016 , 8, 30	11
1242	A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. 2016 , 5, 3	48
1241	Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. 2016 , 23, R267-85	26
1240	SnapShot: Mechanosensing Matrix. 2016 , 165, 1820-1820.e1	39
1239	Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. 2016 , 113, 8272-7	41
1238	OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. 2016 , 17, 128	143
1237	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. 2016 , 21, 848-54	115
1236	CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. 2016 , 15, 2719-32	134
1235	Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. 2016 , 12, 2640-2648	23
1234	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. 2016 , 166, 9-29	22
1233	Contemporary and potential future molecular diagnosis of melanoma. 2016 , 16, 975-85	3
1232	The role of enhancers in cancer. 2016 , 16, 483-93	201
1231	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. 2016 , 35, 1080-9	41
1230	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. 2016 , 3, e1048929	24
1229	Genomic tumor evolution of breast cancer. 2016 , 23, 4-11	19

1228	Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. 2016 , 27, 532-9	20
1227	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. 2016 , 70, 75-82	123
1226	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. 2016 , 37, 4251-61	62
1225	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). 2016 , 387, 1415-1426	581
1224	Polymerase specific error rates and profiles identified by single molecule sequencing. 2016 , 784-785, 39-45	32
1223	A panoply of errors: polymerase proofreading domain mutations in cancer. 2016 , 16, 71-81	205
1222	Translating the molecular diversity of hepatocellular carcinoma into clinical practice. 2016 , 3, e1057316	2
1221	Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. 2016 , 164, 538-49	239
1220	Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. 2016 , 29, 229-40	90
1219	Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo. 2016 , 32, 23-30	45
1218	Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. 2016 , 113, E319-27	62
1217	CRAC channels, calcium, and cancer in light of the driver and passenger concept. 2016 , 1863, 1408-17	38
1216	Polymorphisms in methylenetetrahydrofolate reductase and cystathionine beta-synthase in oral cancer - a case-control study in southeastern Brazilians. 2016 , 82, 558-66	2
1215	Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. 2016 , 14, 298-309	72
1214	BRCAness revisited. 2016 , 16, 110-20	678
1213	Role of non-coding sequence variants in cancer. 2016 , 17, 93-108	301
1212	Somatic mosaicism: on the road to cancer. 2016 , 16, 43-55	77
1211	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. 2016 , 53, 51-64	33

1210	Transmissible Tumors: Breaking the Cancer Paradigm. 2016 , 32, 1-15	48
1209	Timing, rates and spectra of human germline mutation. 2016 , 48, 126-133	338
1208	Substantial contribution of extrinsic risk factors to cancer development. <i>Nature</i> , 2016 , 529, 43-7	50.4 385
1207	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. 2016 , 22, 2226-36	17
1206	Novel therapeutic targets in advanced urothelial carcinoma. 2016 , 98, 106-15	33
1205	Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer. 2016 , 10, 179-93	18
1204	Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area. 2016 , 26, 683-90	53
1203	Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. 2016 , 21, 769-85	10
1202	Personalized therapy for hepatocellular carcinoma: Where are we now?. 2016 , 45, 77-86	45
1201	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. 2016 , 150, 1171-1182	195
1200	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. 2016 , 29, 394-406	81
1199	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. 2016 , 22, 3915-23	73
1198	Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications. 2016 , 17, 41	158
1197	[Immunomodulation as innovative therapy for head and neck tumors : Current developments]. 2016 , 64, 470-8	0
1196	Mutational landscape and underlying mutational processes in chronic lymphocytic leukemia. 2016 , 3, e1157667	8
1195	Improving Systemic Chemotherapy for Bladder Cancer. 2016 , 18, 27	30
1194	Update on Metastatic Uveal Melanoma: Progress and Challenges. 2016 , 30, 161-72	11
1193	Direct observation of proton pumping by a eukaryotic P-type ATPase. 2016 , 351, 1469-73	57

1192	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. 2016 , 141, 86-94	21
1191	Effects of Twelve Germline Missense Variations on DNA Lesion and G-Quadruplex Bypass Activities of Human DNA Polymerase REV1. 2016 , 29, 367-79	9
1190	Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. 2016 , 37, 356-65	30
1189	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. 2016 , 130, 25-74	119
1188	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. 2016 , 14, 907-919	75
1187	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. 2016 , 22, 4746-55	37
1186	Genome-wide kinetics of DNA excision repair in relation to chromatin state and mutagenesis. 2016 , 113, E2124-33	100
1185	Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability. 2016 , 76, 1724-32	86
1184	Genetics and biology of pancreatic ductal adenocarcinoma. 2016 , 30, 355-85	288
1183	RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. 2016 , 14, 44-55	12
1182	Microsatellite Instability as a Biomarker for PD-1 Blockade. 2016 , 22, 813-20	470
1181	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. 2016 , 113, 2170-5	83
1180	PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. 2016 , 27, 755-7	31
1179	APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. 2016 , 33, 26	15
1178	Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. 2016 , 57, 78-86	51
1177	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. 2016 , 10, 893-905	31
1176	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. 2016 , 22, 433-8	531
1175	Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. 2016 , 16, 164-76	109

1174	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. 2016 , 5, e1143997	55
1173	Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma. 2016 , 98, 256-74	87
1172	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. 2016 , 11, 283-312	72
1171	mRNA export protein THOC5 as a tool for identification of target genes for cancer therapy. 2016 , 373, 222-6	7
1170	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. 2016 , 2, 49-63	157
1169	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. 2016 , 22, 2261-70	164
1168	Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. 2016 , 2, e00052	15
1167	Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli. 2016 , 113, 2176-81	58
1166	The three-dimensional cancer genome. 2016 , 36, 1-7	44
1165	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2. 2016 , 22, 3663-71	11
1164	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. 2016 , 22, 262-9	533
1163	Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. 2016 , 15, 477-83	130
1162	Special Techniques. 2016 , 11-44	
1161	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. 2016 , 35, 141-50	22
1160	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. 2016 , 21, 462-73	190
1159	The molecular pathogenesis of chronic lymphocytic leukaemia. 2016 , 16, 145-62	170
1158	Immunotherapy of Cancer. 2016 ,	2
1157	APOBEC3A damages the cellular genome during DNA replication. 2016 , 15, 998-1008	51

1156	The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection. 2016 , 44, 2075-84	42
1155	Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. 2016 , 3, e1029061	5
1154	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. 2016 , 13, 273-90	640
1153	Overview of Current Cancer Immunotherapy. 2016 , 3-17	
1152	[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA]. 2016 , 36, 80-93	5
1151	Mutational Landscape of Aggressive Prostate Tumors in African American Men. 2016 , 76, 1860-8	48
1150	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. 2016 , 4, 452-62	62
1149	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. 2016 , 18, 21	32
1148	Mechanisms underlying structural variant formation in genomic disorders. 2016 , 17, 224-38	331
1147	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. 2016 , 349-358	
1146	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. 2016 , 387, 1909-20	2308
1145	Heterogeneity Among Liver Cancer--A Hurdle to Optimizing Therapy. 2016 , 150, 818-21	4
1144	PrimPol prevents APOBEC/AID family mediated DNA mutagenesis. 2016 , 44, 4734-44	23
1143	Biomarkers in Neoplastic Neuropathology. 2016 ,	
1142	Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. 2016 , 48, 398-406	242
1141	Catalog of genetic progression of human cancers: breast cancer. 2016 , 35, 49-62	14
1140	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 2016 , 15, 235-47	358
1139	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. 2016 , 351, 1463-9	1758

1138	Ratiometric Array of Conjugated Polymers-Fluorescent Protein Provides a Robust Mammalian Cell Sensor. 2016 , 138, 4522-9	98
1137	Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. 2016 , 150, 998-1008	136
1136	Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. 2016 , 48, 117-25	60
1135	Beyond the exome: the role of non-coding somatic mutations in cancer. 2016 , 27, 240-8	24
1134	Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. 2016 , 150, 931-43	156
1133	GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia. 2016 , 29, 61-74	41
1132	APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. 2016 , 26, 174-82	110
1131	Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. 2016 , 18, 190-204	23
1130	Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. 2016 , 890, 123-36	31
1129	Prospects for the use of ipilimumab in treating advanced prostate cancer. 2016 , 16, 421-32	5
1128	Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. 2016 ,	1
1127	Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. 2016 , 27, 635-41	128
1126	Tumor antigens in human cancer control. 2016 , 1865, 83-89	13
1125	Mutanome directed cancer immunotherapy. 2016 , 39, 14-22	44
1124	Overexpression of miR-335 confers cell proliferation and tumour growth to colorectal carcinoma cells. 2016 , 412, 235-45	28
1123	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. 2016 , 37, 141-153	19
1122	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. 2016 , 28, 64-72	41
1121	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 2016 , 34, 155-63	465

1120	Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. 2016 , 22, 105-13	449
1119	Hypermethylation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression. 2016 , 14, 196-206	16
1118	Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. 2016 , 16, 25-38	23
1117	Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. 2016 , 65, 779-86	105
1116	Combination cancer immunotherapies tailored to the tumour microenvironment. 2016 , 13, 143-58	561
1115	Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. 2016 , 6, 430-45	89
1114	Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. 2016 , 27, 344-52	6
1113	Repair Pathway Choices and Consequences at the Double-Strand Break. 2016 , 26, 52-64	788
1112	Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes. 2016 , 238, 98-108	31
1111	Novel immunotherapies in lymphoid malignancies. 2016 , 13, 25-40	172
1110	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. 2016 , 150, 48-63	71
1109	Der Mensch in Zahlen. 2016 ,	7
1108	The influence of subclonal resistance mutations on targeted cancer therapy. 2016 , 13, 335-47	139
1107	Personalized approaches to active immunotherapy in cancer. 2016 , 1865, 72-82	30
1106	Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. 2016 , 5, 12-33	45
1105	MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. 2016 , 35, 1609-18	80
1104	Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer. 2016 , 15, 54-66	5
1103	Advances in personalized cancer immunotherapy. 2017 , 24, 16-24	55

1102	Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. 2017 , 36, 158-167	46
1101	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. 2017 , 14, 115-128	62
1100	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. 2017 , 24, 3-15	107
1099	The importance of DNA methylation in prostate cancer development. 2017 , 166, 1-15	85
1098	Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. 2017 , 176, 498-502	60
1097	Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. 2017 , 25, 392-398	5
1096	Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma. 2017 , 56, 781-788	6
1095	Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). 2017 , 31, 1-10	48
1094	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. 2017 , 7,	16
1093	Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance. 2017 , 97, 698-705	30
1092	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. 2017 , 8, 14121	163
1091	HySA: a Hybrid Structural variant Assembly approach using next-generation and single-molecule sequencing technologies. 2017 , 27, 793-800	20
1090	Genomic analysis and clinical management of adolescent cutaneous melanoma. 2017 , 30, 307-316	11
1089	Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells. 2017 , 77, 1623-1636	8
1088	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , 2017 , 543, 378-384	50.4 755
1087	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. 2017 , 49, 341-348	54
1086	Urinary biomarkers for the diagnosis of urothelial bladder cancer. 2017 , 3, 221	0
1085	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. 2017 , 30, 577-586	88

1084	Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer. 2017 , 162, 31-37	4
1083	[Contribution and challenges of Big Data in oncology]. 2017 , 104, 281-287	1
1082	High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. 2017 , 18, 504-511.e1	10
1081	Genomic insights in gynecologic cancer. 2017 , 41, 8-36	7
1080	HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation. 2017 , 9, 181-197	46
1079	Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. 2017 , 31, 50-63	54
1078	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	50.4 320
1077	Translating genomic profiling to gastrointestinal cancer treatment. 2017 , 13, 919-934	7
1076	Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. 2017 , 145, 176-184	9
1075	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. 2017 , 309-327	1
1074	Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer. 2017 , 11, 124-139	31
1073	Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma. 2017 , 77, 1649-1661	6
1072	is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. 2017 , 129, 1779-1790	14
1071	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. 2017 , 168, 460-472.e14	75
1070	Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues. 2017 , 15, 439-447	38
1069	Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51. 2017 , 591, 1083-1100	92
1068	Human Papillomavirus 16 E6 Upregulates APOBEC3B via the TEAD Transcription Factor. 2017 , 91,	39
1067	Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. 2017 , 331, 1-53	30

1066	Using global gene expression to discriminate thin melanomas with poor outcomes. 2017 , 4, e1253527	1
1065	Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. 2017 , 31, 2181-2190	132
1064	Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. 2017 , 400, 305-323	17
1063	Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. 2017 , 242, 10-15	89
1062	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. 2017 , 63, 532-541	60
1061	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. 2017 , 9, 34-44	9
1060	Evolution of cancer suppression as revealed by mammalian comparative genomics. 2017 , 42, 40-47	31
1059	Genomics of Multiple Myeloma. 2017 , 35, 963-967	68
1058	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. 2017 , 35, 1240-1249	59
1057	Hypermethylation signature reveals a slippage and realignment model of translesion synthesis by Rev3 polymerase in cisplatin-treated yeast. 2017 , 114, 2663-2668	13
1056	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. 2017 , 36, 53-75	29
1055	Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. 2017 , 77, 2255-2265	121
1054	Targeting neoantigens to augment antitumour immunity. 2017 , 17, 209-222	449
1053	One thousand somatic SNVs per skin fibroblast cell set baseline of mosaic mutational load with patterns that suggest proliferative origin. 2017 , 27, 512-523	48
1052	Epidemiology of basal cell carcinoma: scholarly review. 2017 , 177, 359-372	112
1051	Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification. 2017 , 14, 351-362	9
1050	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. 2017 , 23, 3168-3180	51
1049	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. 2017 , 24, R123-R144	45

1048	Assessment of tumor-infiltrating TCRV9V2 lymphocyte abundance by deconvolution of human cancers microarrays. 2017 , 6, e1284723	78
1047	PD-1 and PD-L1 antibodies in cancer: current status and future directions. 2017 , 66, 551-564	188
1046	Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf mouse model. 2017 , 114, 3151-3156	33
1045	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. 2017 , 6, e1299303	14
1044	Non-coding genetic variation in cancer. 2017 , 1, 9-15	23
1043	Efficient Nanovaccine Delivery in Cancer Immunotherapy. 2017 , 11, 2387-2392	192
1042	Molecular features of early onset adult myelodysplastic syndrome. 2017 , 102, 1028-1034	13
1041	B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers. 2017 , 7, 44089	22
1040	Detection of copy number variations in melanocytic lesions utilising array based comparative genomic hybridisation. 2017 , 49, 285-291	21
1039	Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. 2017 , 3, 801-809	51
1038	Immune checkpoint inhibitors in challenging populations. 2017 , 123, 1904-1911	194
1037	Further assessment of exome-wide UVR footprints in melanoma and their possible relevance. 2017 , 56, 1673-1679	1
1036	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. 2017 , 23, 3859-3870	92
1035	Clonal evolution of colorectal cancer in IBD. 2017 , 14, 218-229	77
1034	High expression of PD-1 ligands is associated with mutational signature and APOBEC3 alterations. 2017 , 6, e1284719	42
1033	Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. 2017 , 27, 613-625	18
1032	Endogenous DNA Damage as a Source of Genomic Instability in Cancer. 2017 , 168, 644-656	613
1031	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. 2017 , 168, 613-628	1185

1030	Discovery of Cancer Driver Long Noncoding RNAs across 1112 Tumour Genomes: New Candidates and Distinguishing Features. 2017 , 7, 41544	58
1029	Melanoma genome evolution across species. 2017 , 18, 136	11
1028	Tissue-specific tumorigenesis: context matters. 2017 , 17, 239-253	160
1027	Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. 2017 , 7, 42980	18
1026	Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. 2017 , 114, E2215-E2224	24
1025	Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. 2017 , 6, e1295903	42
1024	Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. 2017 , 14, 19	45
1023	Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. 2017 , 102, 265-275	18
1022	Evolutionary dynamics in pre-invasive neoplasia. 2017 , 2, 1-8	8
1021	Hypermutated Colorectal Cancer and Neoantigen Load. 2017 , 187-215	2
1020	A population genetics perspective on the determinants of intra-tumor heterogeneity. 2017 , 1867, 109-126	29
1019	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. 2017 , 18, 572-582.e1	39
1018	The Current Status of Immunotherapies in Esophagogastric Cancer. 2017 , 26, 277-292	2
1017	APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. 2017 , 31, 2057-2064	39
1016	Monocytes, Macrophages, and Osteoclasts in Osteosarcoma. 2017 , 6, 396-405	42
1015	The evolution of tumour phylogenetics: principles and practice. 2017 , 18, 213-229	137
1014	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. 2017 , 31, 286-299	240
1013	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. 2017 , 54, 68-73	52

1012	Transgenic rat models for mutagenesis and carcinogenesis. 2017 , 39, 11	27
1011	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. 2017 , 31, 2048-2056	29
1010	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017 , 543, 65-71	50.4 482
1009	Cancer Genomics and Evolution. 2017 , 1-27	0
1008	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. 2017 , 356, 200-205	231
1007	Nuclear Proximity of Mtr4 to RNA Exosome Restricts DNA Mutational Asymmetry. 2017 , 169, 523-537.e15	31
1006	Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. 2017 , 108, 610-626	116
1005	Tangible mtDNA. 2017 ,	1
1004	Gene and Variant Annotation for Mendelian Disorders in the Era of Advanced Sequencing Technologies. 2017 , 18, 229-256	32
1003	Natural and Chemotherapy-Induced Clonal Evolution of Tumors. 2017 , 82, 413-425	18
1002	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. 2017 , 9, 34	1509
1001	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. 2017 , 8, 14944	79
1000	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. 2017 , 97, 130-145	25
999	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. 2017 , 49, 856-865	141
998	Identification of Immunogenic Epitopes by MS/MS. 2017 , 23, 102-107	17
997	Variability in Chromatin Architecture and Associated DNA Repair at Genomic Positions Containing Somatic Mutations. 2017 , 77, 2822-2833	12
996	Cutaneous malignant melanoma incidences analyzed worldwide by sex, age, and skin type over personal Ultraviolet-B dose shows no role for sunburn but implies one for Vitamin D. 2017 , 9, e1267077	7
995	Environmental influences in the etiology of colorectal cancer: the premise of metabolomics. 2017 , 3, 114-125	23

994	Intrinsic Molecular Processes: Impact on Mutagenesis. 2017 , 3, 357-371	4
993	An alternative model for (breast) cancer predisposition. 2017 , 3, 13	3
992	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. 2017 , 23, 115-124	7
991	Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. 2017 , 23, 125-130	15
990	Neoantigen Discovery in Human Cancers. 2017 , 23, 97-101	5
989	Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma. 2017 , 28, 890-897	33
988	Self-cytoplasmic DNA upregulates the mutator enzyme APOBEC3A leading to chromosomal DNA damage. 2017 , 45, 3231-3241	20
987	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. 2017 , 71, 480-487	2
986	An evolutionary case for functional gene body methylation in plants and animals. 2017 , 18, 87	87
985	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. 2017 , 38, 513-525	58
984	Mutational signatures and mutable motifs in cancer genomes. 2018 , 19, 1085-1101	25
983	Postzygotic single-nucleotide mosaicisms contribute to the etiology of autism spectrum disorder and autistic traits and the origin of mutations. 2017 , 38, 1002-1013	37
982	PGBD5 promotes site-specific oncogenic mutations in human tumors. 2017 , 49, 1005-1014	40
981	Genetic and epigenetic profiling of a solitary Peutz-Jeghers colon polyp. 2017 , 3, a001610	7
980	Exploring background mutational processes to decipher cancer genetic heterogeneity. 2017 , 45, W514-W522	41
979	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. 2017 , 23, 703-713	1638
978	Rethinking cancer nanotheranostics. 2017 , 2,	639
977	TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. 2017 , 4, 170050	37

976	The swinging pendulum of cancer immunotherapy personalization. 2017 , 14, 259-270	3
975	Molecular diagnoses of century-old childhood tumours. 2017 , 18, e237	2
974	Family-Wide Comparative Analysis of Cytidine and Methylcytosine Deamination by Eleven Human APOBEC Proteins. 2017 , 429, 1787-1799	41
973	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. 2017 , 13, 1765-1767	2
972	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. 2017 , 77, 3540-3550	213
971	Personalized T cell-mediated cancer immunotherapy: progress and challenges. 2017 , 48, 142-152	68
970	Chronic viral hepatitis and its association with liver cancer. 2017 , 398, 817-837	55
969	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. 2017 , 114, E4030-E4039	42
968	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. 2017 , 6, e1321184	20
967	Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. 2017 , 28, 1597-1604	22
966	A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. 2017 , 27, 902-912	14
965	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017 , 545, 175-180	50.4 662
964	Immunotherapy in genitourinary malignancies. 2017 , 10, 95	25
963	APOBEC3A efficiently deaminates methylated, but not TET-oxidized, cytosine bases in DNA. 2017 , 45, 7655-7665	35
962	4-1BB-Enhanced Expansion of CD8 TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 T Cells. 2017 , 5, 439-445	32
961	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. 2017 , 134, 155-158	19
960	Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?. 2017 , 11, 683-694	4
959	Stem cells: Subclone wars. <i>Nature</i> , 2017 , 545, 160-161	50.4 1

958	Rational design of non-resistant targeted cancer therapies. 2017 , 7, 46632	9
957	Tracking the Evolution of Non-Small-Cell Lung Cancer. 2017 , 376, 2109-2121	1156
956	Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. 2017 , 133, 277-285	32
955	Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration. 2017 , 2, 103-114	29
954	Melanoma: a global perspective. 2017 , 17, 393-394	65
953	Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. 2017 , 12, 1098-1108	14
952	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. 2017 , 7, 832-851	31
951	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors. 2017 , 7, 999-1005	158
950	Lung Carcinoma Staging Update. 2017 , 141, 923-926	1
949	Molecular Genetics of Endometrial Carcinoma. 2017 ,	1
948	Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions. 2017 , 31, 1-12	10
947	Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. 2017 , 77, 425-434	3
946	Next-Generation Sequencing. 2017 , 943, 119-148	31
945	Non-heme dioxygenases in tumor hypoxia: They're all bound with the same fate. 2017 , 49, 21-25	8
944	Resistance to PD1/PDL1 checkpoint inhibition. 2017 , 52, 71-81	305
943	Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma. 2017 , 137, 905-909	29
942	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. 2017 , 169, 1327-1341. e235	
941	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. 2017 , 56, 16-25	51

940	Breast Cancer Neoantigens Can Induce CD8 T-Cell Responses and Antitumor Immunity. 2017 , 5, 516-523	40
939	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. 2017 , 14, 1248-1260	10
938	Modeling Therapy Resistance in -Mutant Cancers. 2017 , 16, 2022-2034	44
937	Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. 2017 , 26, 3014-3027	64
936	Enhanced Rate of Acquisition of Point Mutations in Mouse Intestinal Adenomas Compared to Normal Tissue. 2017 , 19, 2185-2192	15
935	Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. 2017 , 109,	57
934	Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression. 2017 , 109,	18
933	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. 2017 , 19, 45	58
932	Human mismatch repair system balances mutation rates between strands by removing more mismatches from the lagging strand. 2017 , 27, 1336-1343	22
931	Identification of a novel somatic mutation in a -mutated corticotroph adenoma. 2017 , 3, a001602	7
930	Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline :c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. 2017 , 3,	6
929	Models in Translational Oncology: A Public Resource Database for Preclinical Cancer Research. 2017 , 77, 2557-2563	20
928	and are the most frequently mutated genes in paraganglioma and pheochromocytoma tumors. 2017 , 24, L57-L61	6
927	Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. 2017 , 18, 451-469	20
926	Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. 2017 , 117, 136-143	25
925	Utilizing next-generation sequencing in the management of multiple myeloma. 2017 , 17, 653-663	18
924	Therapeutic Vaccine of Gastric Cancer. 2017 , 131-147	
923	Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD. 2017 , 7, 2121	18

922	Is the Genetic Paradigm of Cancer Complete?. 2017 , 284, 1-3	15
921	Oesophageal cancer. 2017 , 390, 2383-2396	489
920	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. 2017 , 82, 56-65	109
919	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. 2017 , 8, 15936	125
918	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. 2017 , 23, 2611-2616	14
917	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. 2017 , 23, e38-e45	245
916	Evolving adoptive cellular therapies in urological malignancies. 2017 , 18, e341-e353	16
915	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. 2017 , 20, 39-49	112
914	Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. 2017 , 72, 641-649	111
913	Treatment strategies for DNA repair-deficient prostate cancer. 2017 , 10, 889-898	21
912	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. 2017 , 9,	167
911	Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution. 2017 , 15, 1127-1137	31
910	Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. 2017 , 53, 48-58	13
909	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. 2017 , 5, 23	87
908	Unravelling the biology of SCLC: implications for therapy. 2017 , 14, 549-561	209
907	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. 2017 , 7, 2074	14
906	The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes. 2017 , 45, 7786-7795	50
905	Matrix Mechanosensing: From Scaling Concepts in 'Omics Data to Mechanisms in the Nucleus, Regeneration, and Cancer. 2017 , 46, 295-315	62

904	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. 2017 , 117, 113-123	59
903	Therapeutic T cell engineering. <i>Nature</i> , 2017 , 545, 423-431	50.4 420
902	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. 2017 , 70, 34-42	29
901	Immune and molecular correlates in melanoma treated with immune checkpoint blockade. 2017 , 123, 2143-2153	80
900	Interaction of molecular alterations with immune response in melanoma. 2017 , 123, 2130-2142	18
899	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. 2017 , 34, 83-88	17
898	Modeling the process of human tumorigenesis. 2017 , 8, 15422	35
897	Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. 2017 , 8, 15290	109
896	The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. 2017 , 102, 1617-1625	42
895	Genomic landscape of high-grade meningiomas. 2017 , 2,	78
894	Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma. 2017 , 108, 256-266	12
893	Emerging drugs for urothelial (bladder) cancer. 2017 , 22, 149-164	7
892	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. 2017 , 108, 1022-1031	66
891	Modelling Molecular Mechanisms of Cancer Pathogenesis: Virtual Patients, Real Opportunities. 2017 , 359-374	
890	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. 2017 , 34, 121	11
889	Gastric adenocarcinoma. 2017 , 3, 17036	251
888	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. 2017 , 214, 2073-2088	23
887	Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer. 2017 , 23, 2630-2639	15

886	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. 2017 , 23, 2617-2629	73
885	The promising impact of molecular profiling on treatment strategies in oral cancers. 2017 , 118, 242-247	11
884	Elastic-Fluid Model for DNA Damage and Mutation from Nuclear Fluid Segregation Due to Cell Migration. 2017 , 112, 2271-2279	20
883	Melanocytic nevi and melanoma: unraveling a complex relationship. 2017 , 36, 5771-5792	87
882	Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. 2017 , 123, 3807-3815	99
881	Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma. 2017 , 242, 500-510	31
880	Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. 2017 , 130, 699-712	95
879	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. 2017 , 16, 1610-1622	16
878	Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. 2017 , 103, 1750-1757	22
877	Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. 2017 , 153, 249-262.e2	72
876	Chromatin marks shape mutation landscape at early stage of cancer progression. 2017 , 2, 9	7
875	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. 2017 , 28, 1130-1136	186
874	Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. 2017 , 28, 1070-1077	35
873	A comprehensive quality control workflow for paired tumor-normal NGS experiments. 2017 , 33, 1721-1722	8
872	Integrated genomic analyses reveal frequent aberrations in acral melanoma. 2017 , 27, 524-532	78
871	Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. 2017 , 77, 84-87	30
870	Precancer Atlas to Drive Precision Prevention Trials. 2017 , 77, 1510-1541	81
869	Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient. 2017 , 69, 1-10	5

868	Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer. 2017 , 7,	31
867	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. 2017 , 123, 1912-1924	36
866	Immune engineering: from systems immunology to engineering immunity. 2017 , 1, 54-62	3
865	Cancer: Bad Luck or Punishment?. 2017 , 82, 75-80	4
864	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. 2017 , 134, 297-316	17
863	APOBEC3B cytidine deaminase targets the non-transcribed strand of tRNA genes in yeast. 2017 , 53, 4-14	23
862	Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. 2017 , 1867, 162-166	29
861	Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. 2017 , 67, 186-191	6
860	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. 2017 , 30, 952-963	37
859	Detection of cytosine and CpG density in proto-oncogenes and tumor suppressor genes in promoter sequences of acute myeloid leukemia. 2017 , 36, 302-316	0
858	Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. 2017 , 23, 4347-4353	21
857	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. 2017 , 23, 1638-1646	92
856	Unleashing the immune response against childhood solid cancers. 2017 , 64, e26548	5
855	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. 2017 , 28, 1243-1249	17
854	High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. 2017 , 141, 184-190	4
853	The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer. 2017 , 31, 485-498	3
852	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. 2017 , 2,	82
851	Cancer-associated noncoding mutations affect RNA G-quadruplex-mediated regulation of gene expression. 2017 , 7, 708	19

850	Avoidance of APOBEC3B-induced mutation by error-free lesion bypass. 2017 , 45, 5243-5254	14
849	The new frontier of epigenetic heterogeneity in B-cell neoplasms. 2017 , 24, 402-408	9
848	Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. 2017 , 23, 4493-4500	12
847	Longitudinal analysis of treatment-induced genomic alterations in gliomas. 2017 , 9, 12	15
846	Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma. 2017 , 153, 166-177	78
845	Mutational spectra of aflatoxin B in vivo establish biomarkers of exposure for human hepatocellular carcinoma. 2017 , 114, E3101-E3109	58
844	Molecular genetic and immunotherapeutic targets in metastatic melanoma. 2017 , 471, 281-293	14
843	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. 2017 , 31, 476-485	86
842	Immunotherapy for gastric cancers: emerging role and future perspectives. 2017 , 10, 609-619	26
841	Comprehensive somatic genome alterations of urachal carcinoma. 2017 , 54, 572-578	20
840	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. 2017 , 23, 4402-4415	69
839	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. 2017 , 9, 423-433	6
838	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. 2017 , 23, 517-525	444
837	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. 2017 , 7,	32
836	Translational applications of adult stem cell-derived organoids. 2017 , 144, 968-975	72
835	Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma. 2017 , 37, 1591-1601	11
834	Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. 2017 , 242, 165-177	35
833	A Regulatory Role for RUNX1, RUNX3 in the Maintenance of Genomic Integrity. 2017 , 962, 491-510	7

832	NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. 2017 , 11, 438-451	73
831	Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer. 2017 , 3, 1-7	7
830	A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. 2017 , 49, 730-741	34
829	Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. 2017 , 36, 4161-4170	51
828	Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation. 2017 , 27, 501-511	31
827	Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective. 2017 , 3, 359-366	4
826	Radiotherapy plus EGFR inhibitors: synergistic modalities. 2017 , 2, 2	3
825	Current and Emerging Molecular Tests for Human Papillomavirus-Related Neoplasia in the Genomic Era. 2017 , 19, 366-377	12
824	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017 , 543, 714-718	50.4 157
823	Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. 2017 , 64, e26365	34
822	Genomic pathobiology of gastric carcinoma. 2017 , 67, 63-71	8
821	Immuno-Oncology: The Third Paradigm in Early Drug Development. 2017 , 12, 125-138	16
820	Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. 2017 , 152, 983-986.e6	69
819	Preclinical approaches in chronic myeloid leukemia: from cells to systems. 2017 , 47, 13-23	21
818	Modeling cancer rearrangement landscapes. 2017 , 1, 54-61	10
817	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. 2017 , 7, 264-276	49 ¹
816	Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides. 2017 , 429, 88-96	3
815	Statistical Methods for Identifying Sequence Motifs Affecting Point Mutations. 2017 , 205, 843-856	14

814	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. 2017 , 152, 745-761	535
813	Immunotherapy for Gastrointestinal Cancer. 2017 ,	0
812	DNA damage repair in breast cancer and its therapeutic implications. 2017 , 49, 156-165	36
811	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). 2017 , 18, 333-339	32
810	T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. 2017 , 38, 104-115	64
809	Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes. 2017 , 100, 5-20	58
808	Alternative roles for oxidized mCs and TETs. 2017 , 42, 1-7	21
807	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. 2017 , 6, e1260214	5
806	APOBEC3A/B-induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context. 2017 , 27, 175-184	19
805	Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. 2017 , 140, 1356-1363	18
804	Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. 2017 , 23, 3012-3024	442
803	Integrated genomic characterization of oesophageal carcinoma. <i>Nature</i> , 2017 , 541, 169-175	50.4 965
802	Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. 2017 , 8,	73
801	Tissue disruption increases stochastic gene expression thus producing tumors: Cancer initiation without driver mutation. 2017 , 140, 2408-2413	16
800	Immunoplasticity in cutaneous melanoma: beyond pure morphology. 2017 , 470, 357-369	2
799	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. 2017 , 6, e1264565	79
798	Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. 2017 , 24, 131-139	141
797	Looking beyond drivers and passengers in cancer genome sequencing data. 2017 , 28, 938-945	22

796	Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing. 2017 , 36, 2857-2867	38
795	Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. 2017 , 144, 377-383	32
794	Radiation-associated neoplasia: clinical, pathological and genomic correlates. 2017 , 70, 70-80	54
793	A new molecular paradigm in mycosis fungoides and Sézary syndrome. 2017 , 34, 15-21	19
792	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. 2017 , 171, 1259-1271.e11	541
791	DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. 2017 , 15, 1063-1069	19
790	Small-cell lung cancer: what we know, what we need to know and the path forward. 2017 , 17, 725-737	286
789	Somatic mutation driven codon transition bias in human cancer. 2017 , 7, 14204	5
788	Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer. 2017 , 23, 7596-7607	9
787	Nuclear topology modulates the mutational landscapes of cancer genomes. 2017 , 24, 1000-1006	22
786	Combating subclonal evolution of resistant cancer phenotypes. 2017 , 8, 1231	79
785	Sortilin limits EGFR signaling by promoting its internalization in lung cancer. 2017 , 8, 1182	38
784	[Prostate cancer and DNA repair genes]. 2017 , 104, 958-961	0
783	Contributions of the Intrinsic Mutation Process to Cancer Mutation and Risk Burdens. 2017 , 24, 5-6	6
782	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. 2017 , 23, 7633-7640	13
781	NGS-based analysis of base-substitution signatures created by yeast DNA polymerase eta and zeta on undamaged and abasic DNA templates in vitro. 2017 , 59, 34-43	4
780	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 1240-1267	172
779	The promises of immunotherapy in gliomas. 2017 , 30, 650-658	10

778	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. 2017 , 32, 506-519.e5	146
777	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. 2017 , 171, 540-556.e25	961
776	A genetic roadmap of pancreatic cancer: still evolving. 2017 , 66, 2170-2178	32
775	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. 2017 , 8, 823	29
774	Genetic variants affecting equivalent protein family positions reflect human diversity. 2017 , 7, 12771	7
773	Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. 2017 , 15, 1277-1284	20
772	A Review of Stochastic and Delay Simulation Approaches in Both Time and Space in Computational Cell Biology. 2017 , 241-261	1
771	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. 2017 , 8, 857	129
770	4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. 2017 , 23, 7263-7275	29
769	Cancer: Bad blood promotes tumour progression. <i>Nature</i> , 2017 , 549, 465-466	50.4 2
768	Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer. 2017 , 77, 6551-6561	14
767	A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. 2017 , 37, 1391-1405	11
766	Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns. 2017 , 171, 321-330.e14	263
765	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39	29
764	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. 2017 , 86, 5-14	28
763	The driver landscape of sporadic chordoma. 2017 , 8, 890	64
762	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. 2017 , 7, 1420-1435	302
761	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. 2017 , 171, 934-949.e16	831

760	Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. 2017 , 280, 231-248	88
759	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
758	Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. 2017 , 9,	184
757	Universal Patterns of Selection in Cancer and Somatic Tissues. 2017 , 171, 1029-1041.e21	576
756	Comprehensive Analysis of Hypermutation in Human Cancer. 2017 , 171, 1042-1056.e10	417
755	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. 2017 , 1868, 527-537	29
754	LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. 2017 , 28, 2977-2984	93
753	The genomic and epigenomic landscape in thymic carcinoma. 2017 , 38, 1084-1091	31
752	The growth of molecular diagnostics: Stratified Medicine Programme, the 100,000 Genomes Project and the future. 2017 , 23, 458-467	2
751	Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. 2017 , 28, 2950-2961	56
750	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. 2017 , 28, 3015-3021	52
749	Checkpoint immunotherapy in head and neck cancers. 2017 , 36, 475-489	27
748	Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. 2017 , 60, 44-52	62
747	Unravelling biology and shifting paradigms in cancer with single-cell sequencing. 2017 , 17, 557-569	157
746	Therapy-related myeloid neoplasms: when genetics and environment collide. 2017 , 17, 513-527	150
745	Evolutionary biology of high-risk multiple myeloma. 2017 , 17, 543-556	119
744	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. 2017 , 16, 2598-2608	1183
743	Nucleotide Excision Repair: From Neurodegeneration to Cancer. 2017 , 1007, 17-39	15

742	Immunotherapy in Gynecologic Cancers: Are We There Yet?. 2017 , 18, 59	33
741	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. 2017 , 19, 1093-1104	43
740	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. 2017 , 49, 1476-1486	255
739	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. 2017 , 17, 951-964	1
738	Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?. 2017 , 27, 566-571	9
737	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. 2017 , 84, 290-303	89
736	The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. 2017 , 77, 6144-6156	9
735	Molecular Characteristics of Patient-Derived Tumor Xenografts: Similarities to Patient Tumors and Relevance for Biomarker Discovery. 2017 , 227-243	1
734	CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. 2017 , 66, 1609-1617	51
733	Exonic Mosaic Mutations Contribute Risk for Autism Spectrum Disorder. 2017 , 101, 369-390	103
732	WITHDRAWN: Epigenetics in Chronic Liver Disease. 2017 ,	
731	Implications of CRISPR-Based Germline Engineering for Cancer Survivors. 2017 , 51, 672-682	1
730	Greener revolutions for all require transparency and diversity, not secrecy. 2017 , 35, 817-818	1
729	Classifying the evolutionary and ecological features of neoplasms. 2017 , 17, 605-619	208
728	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. 2017 , 218-219, 39-50	33
727	Estimating the human mutation rate from autozygous segments reveals population differences in human mutational processes. 2017 , 8, 303	52
726	Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. 2017 , 74, 8-14	31
725	Parental influence on human germline de novo mutations in 1,548 trios from Iceland. <i>Nature</i> , 2017 , 549, 519-522	50.4 223

724	APOBEC: From mutator to editor. 2017 , 44, 423-437	37
723	Rebuilding Chromosomes After Catastrophe: Emerging Mechanisms of Chromothripsis. 2017 , 27, 917-930	113
722	PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo. 2017 , 9, 805-817	15
721	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. 2017 , 187, 2246-2258	66
720	Analysis of somatic microsatellite indels identifies driver events in human tumors. 2017 , 35, 951-959	72
719	KRAS Alleles: The Devil Is in the Detail. 2017 , 3, 686-697	156
718	Neoantigen prediction and the need for validation. 2017 , 35, 815-817	48
717	Accurate and sensitive mutational signature analysis with MuSiCal.	
716	Genomic and transcriptomic landscape of advanced renal cell cancer to individualize treatment strategy.	
715	Apurinic/aprimidinic nuclease 1 drives genomic evolution contributing to chemoresistance and tumorigenesis in solid tumor.	0
714	Mutational impact of APOBEC3B and APOBEC3A in a human cell line.	2
713	Single-cell mosaicism analysis reveals cell-type-specific somatic mutational burden in Alzheimer's Dementia.	0
712	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. 2022 ,	2
711	PhiDsc: Protein functional mutation Identification by 3D Structure Comparison.	
710	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. 2022 , 14, 2562	1
709	Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. 2022 , 14, 2504	1
708	FSTruct : an F ST -based tool for measuring ancestry variation in inference of population structure.	
707	Comprehensive machine-learning survival framework develop a consensus model in large scale multi-center cohorts for pancreatic cancer.	

706	NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme. 2022 , 23, 5857	0
705	Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.	1
704	Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL). 2022 , 14, 2474	1
703	APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types. 2022 , 20,	0
702	Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. 2022 ,	1
701	Genetic layout of melanoma lesions associates to BRAF/MEK-targeted therapy resistance and to transcriptional profiles. 2022 ,	1
700	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. 2022 , 14, 2710	1
699	Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure.	
698	Topography of mutational signatures in human cancer.	0
697	Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. 2022 , 14, 2578	2
696	Obstacles and Opportunities for Base Excision Repair in Chromatin. 2022 , 103345	1
695	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. 2022 ,	1
694	Mutational signatures are markers of drug sensitivity of cancer cells. 2022 , 13,	2
693	Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. 2022 , 14, 2545	3
692	Epigenetics Regulates Antitumor Immunity in Melanoma. 2022 , 13,	1
691	Examining clustered somatic mutations with SigProfilerClusters.	1
690	Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules.	0
689	The evolution of two transmissible cancers in Tasmanian devils.	0

- 688 A local human V α T cell population is associated with survival in nonsmall-cell lung cancer. 1
- 687 Immunologische Biomarkerforschung in der Uronkologie (Beispiel Urothelkarzinom).
- 686 Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. **2022**, 14, 4
- 685 In utero origin of myelofibrosis presenting in adult monozygotic twins. 3
- 684 Apport de l'immunoth rapie dans les tumeurs pulmonaires neuroendocrines   petites cellules. **2022**, 14, 1S23-1S31
- 683 Clinical implications of homologous recombination repair mutations in prostate cancer. **2022**, 82, 1
- 682 The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers. **2022**, 13, 3
- 681 APOBEC mutagenesis is low in most types of non-B DNA structures. **2022**, 104535 0
- 680 Homologous recombination deficiency and molecular subtype are associated with immunogenicity in ovarian cancer.
- 679 Restructuring of Lamina-Associated Domains in Senescence and Cancer. **2022**, 11, 1846 2
- 678 Immune complexome analysis of serum samples from non-small-cell lung cancer patients identifies predictive biomarkers for nivolumab therapy. **2022**,
- 677 PRC2 clock: a universal biomarker of aging and rejuvenation. 0
- 676 De quelques th ories de l'oncog n se. **2022**,
- 675 Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. **2022**, 14, 2775 0
- 674 Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment. 0
- 673 Unifying Concept of Genomic Changes: The Mutational Landscape of Cancers. **2022**, 15-20
- 672 Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope. **2022**, 393-411
- 671 Immunotherapy in Melanoma and Merkel Cell Cancer. **2022**, 709-718

670	Experience with atezolizumab combination therapy for small cell lung cancer: analysis of the authors' own data. 2022 , 11, 36	
669	Hallmarks of Cancer: Molecular Underpinnings. 2022 , 3-14	0
668	Clinical and Molecular Features of Pediatric Cancer Patients with Lynch Syndrome.	0
667	Recent Advances and Challenges in Uveal Melanoma Immunotherapy. 2022 , 14, 3094	3
666	Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas. 2022 , 8,	0
665	Clinical Implications of Necroptosis Genes Expression for Cancer Immunity and Prognosis: A Pan-Cancer Analysis. 13,	0
664	Genomic characterization of lymphomas in patients with inborn errors of immunity.	4
663	Complex Mutation Profiles in Mismatch Repair and Ribonucleotide Reductase Mutants Reveal Novel Repair Substrate Specificity of MutS Homolog (MSH) Complexes.	0
662	Whole genome and transcriptome analysis enhances precision cancer treatment options. 2022 ,	1
661	Gene signature for predicting homologous recombination deficiency in triple-negative breast cancer.	
660	APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer. 2022 , 14, 2827	0
659	APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?. 2022 , 9,	0
658	PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas. 12,	
657	Cross Analysis of Genomic-Pathologic Features on Multiple Primary Hepatocellular Carcinoma. 13,	
656	Proteogenomic Characterization of Cholangiocarcinoma.	0
655	Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.. 2022 , 100090	
654	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). 2022 , 6,	2
653	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	1

652	Vaccines for immunoprevention of DNA mismatch repair deficient cancers. 2022 , 10, e004416	3
651	Measuring thermodynamic preferences to form non-native conformations in nucleic acids using ultraviolet melting. 2022 , 119,	0
650	Signatures of copy number alterations in human cancer. <i>Nature</i> ,	50.4 4
649	A phylogenetic approach to study the evolution of somatic mutational processes in cancer. 2022 , 5,	0
648	Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures. 2022 , 13,	0
647	Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma. 2022 , 52, 1103-1104	
646	Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. 2022 , 11,	0
645	Identifying the Potential Roles of PBX4 in Human Cancers Based on Integrative Analysis. 2022 , 12, 822	
644	Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease.	0
643	Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions. 12,	
642	Genome-wide mapping of somatic mutation rates uncovers drivers of cancer.	1
641	Heterogeneity in Melanoma. 2022 , 14, 3030	0
640	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. 2022 , 11, 3364	0
639	Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.	2
638	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?.	1
637	Therapy of genomic unstable solid tumours (WHO grade 3/4)in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial. 2022 , 12, e055742	
636	Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy. 2201895	2
635	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. 2022 , 13,	3

- 634 Loss of MMR and TGFBR2 Increases the Susceptibility to Microbiota-Dependent Inflammation-Associated Colon Cancer. **2022**, 0
- 633 Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. 0
- 632 Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?. **2022**, 20, 663-673.e12
- 631 Treatment represents a key driver of metastatic cancer evolution. 0
- 630 Evaluating multiple next-generation sequencing derived tumor features to accurately predict DNA mismatch repair status.
- 629 Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. **2022**, 14, 3092 0
- 628 The origin of bladder cancer from mucosal field effects. **2022**, 25, 104551 0
- 627 Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. **2022**, 109, 102429 2
- 626 Immune checkpoint inhibitors combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis. 1
- 625 Radon and Lung Cancer: Current Trends and Future Perspectives. **2022**, 14, 3142 1
- 624 The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. **2022**, 23, 7066 0
- 623 Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. 13, 1
- 622 The impact of rare germline variants on human somatic mutation processes. **2022**, 13, 0
- 621 Cancer Risk and Mutational Patterns Following Organ Transplantation. 10, 0
- 620 DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary.
- 619 Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options. **2022**, 0
- 618 Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. 0
- 617 Hepatocellular Carcinoma.

- 616 Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. **2022**, 1
- 615 Descriptive, analytical and molecular epidemiology of pancreatic cancer. **2022**, 21, 90-103
- 614 Pan-Cancer Analysis for Immune Cell Infiltration and Mutational Signatures Using Non-Negative Canonical Correlation Analysis. **2022**, 12, 6596
- 613 Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. **2022**, 14, 3213 1
- 612 Oxidative-Stress-Sensitive microRNAs in UV-Promoted Development of Melanoma. **2022**, 14, 3224 0
- 611 Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025. 0
- 610 A deep learning approach for improved detection of homologous recombination deficiency from shallow genomic profiles.
- 609 Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. OF1-OF12
- 608 Germline De Novo Mutations as a Cause of Childhood Cancer. **2022**, 0
- 607 Driver Gene Alterations in Malignant Progression of Gastric Cancer. 12,
- 606 Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure. **2022**, 13, 0
- 605 Game of clones: Battles in the field of carcinogenesis. **2022**, 108251 0
- 604 Neoantigens and NK Cells: Trick or Treat? The Cancers?. 13, 1
- 603 Single-Cell Transcriptomic Analysis Reveals the Crosstalk Propensity Between the Tumor Intermediate State and the CD8+ T Exhausted State to be Associated with Clinical Benefits in Melanoma. 13,
- 602 Computational construction of TME -related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. 0
- 601 Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. 13,
- 600 Acetaldehyde makes a distinct mutation signature in single-stranded DNA. 0
- 599 HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. 0

598	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. 2022 , 10, e005041	3
597	The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.	0
596	Clinical, pathological, and molecular prognostic factors in patients with early-stage EGFR mutant NSCLC.	1
595	Iris and ciliary body melanocytomas are defined by solitary GNAQ mutation without additional oncogenic alterations. 2022 ,	
594	Chromatin and the Cellular Response to Particle Radiation-Induced Oxidative and Clustered DNA Damage. 10,	1
593	Connecting Metabolic Rewiring With Phenotype Switching in Melanoma. 10,	0
592	Facts and hopes for immunotherapy in renal cell carcinoma.	2
591	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. 2022 , 54, 996-1012	4
590	Case Report: Malignant Brain Tumors in Siblings With MSH6 Mutations. 12,	
589	Katdetectr: utilising unsupervised changepoint analysis for robust kataegis detection.	
588	Mutational spectra analysis reveals bacterial niche and transmission routes.	0
587	Turnover shapes evolution of birth and death rates.	0
586	Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ? variants at low dNTP levels.	
585	Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. 2022 , 14,	3
584	Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma. 12,	0
583	Childhood cancer mutagenesis caused by a domesticated DNA transposase.	
582	Immunotherapy and breast cancer: an overview. Publish Ahead of Print,	2
581	PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.	

- 580 DNA methylation alterations across time and space in paediatric brain tumours. **2022**, 10, 0
- 579 Ovarialkarzinom: Immuntherapie, quo vadis?.
- 578 Evolution of ipsilateral breast cancer decoded by proteogenomics
- 577 Application of non-negative matrix factorization in oncology: one approach for establishing precision medicine. **2022**, 23, 2
- 576 Enabling Inference for Context-Dependent Models of Mutation by Bounding the Propagation of Dependency.
- 575 The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage Small Cell Lung Cancer. **2022**, 100373
- 574 Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. **2022**, 7, 100540 1
- 573 Single-cell sequencing reveals CD133+CD44^{hi}originating evolution and novel stemness related variants in human colorectal cancer. **2022**, 82, 104125 0
- 572 A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. **2022**, 110, 108846
- 571 KMT2C-deficient tumors have elevated APOBEC mutagenesis and genomic instability in multiple cancers. **2022**, 4, 1
- 570 A redox-sensitive iron-sulfur cluster in murine FAM72A controls its ability to degrade the nuclear form of uracil-DNA glycosylase. **2022**, 103381
- 569 Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology. **2022**, 14, 3628 0
- 568 Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. 1
- 567 Current State of Cell Therapies for Genitourinary Malignancies. **2022**, 28, 294-300 0
- 566 Site-Specific Considerations on Engineered T Cells for Malignant Gliomas. **2022**, 10, 1738 3
- 565 Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy. **2022**, 10, e004831 0
- 564 Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites. 13, 1
- 563 Human Variation in DNA Repair, Immune Function, and Cancer Risk. 13,

562	Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.		
561	Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastoma.		
560	A quantification method of somatic mutations in normal tissues and their accumulation in pediatric patients with chemotherapy. 2022 , 119,		0
559	Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. 2022 , 10, e004638		0
558	The APE2 nuclease is essential for DNA double strand break repair by microhomology-mediated end-joining.		1
557	Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma. Publish Ahead of Print,		
556	Mechanisms of APOBEC3 mutagenesis in human cancer cells. <i>Nature</i> , 2022 , 607, 799-807	50.4	11
555	Molecular Features in Lymphatic Metastases Reflect the Metastasis Mechanism of Lymph Nodes With Non-Small-Cell Lung Cancers. 10,		0
554	Extended family with germline pathogenic variant in polymerase delta provides strong evidence for recessive effect of proofreading inactivation.		0
553	Duplex sequencing identifies genomic features that determine susceptibility to benzo(a)pyrene-induced in vivo mutations. 2022 , 23,		0
552	Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. 2022 , 28, 322-327		
551	Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. 2022 , 14, 957-983		1
550	Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. 2022 , 237, 108253		3
549	Identify non-mutational p53 loss of function in human cancers.		
548	Linking neural crest development to neuroblastoma pathology. 2022 , 149,		0
547	Clinical implications of genetic testing in familial intermediate and late-onset colorectal cancer.		
546	The molecular landscape of pancreatic ductal adenocarcinoma. 2022 ,		0
545	The shaping of cancer genomes with the regional impact of mutation processes. 2022 , 54, 1049-1060		0

- 544 SECEDO: SNV-based subclone detection using ultra-low coverage single-cell DNA sequencing.
- 543 Basic premises: searching for new targets and strategies in diffuse gliomas. 0
- 542 Breaking the aging epigenetic barrier. 10, 0
- 541 Aristolochic acid-associated cancers: a public health risk in need of global action. 2
- 540 Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models. 1
- 539 Establishing Linkages Among DNA Damage, Mutagenesis, and Genetic Diseases. 1
- 538 Biased distribution of action-at-a-distance mutations by 8-oxo-7,8-dihydroguanine. **2022**, 825, 111794 0
- 537 Deficient DNA base-excision repair in the forebrain leads to a sex-specific anxiety-like phenotype in mice. **2022**, 20, 0
- 536 Proton and alpha radiation-induced mutational profiles in human cells.
- 535 Widespread perturbation of ETS factor binding sites in cancer.
- 534 Nischarin expression may have differing roles in male and female melanoma patients.
- 533 Effect of Smoking on Treatment Efficacy and Toxicity in Patients with Cancer: A Systematic Review and Meta-Analysis. **2022**, 14, 4117 0
- 532 Construction of Circadian Clock Signature for Tumor Microenvironment in Predicting Survival for Cutaneous Melanoma. **2022**, 28, 2349-2361
- 531 Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. 13, 0
- 530 A patient-driven clinicogenomic partnership for metastatic prostate cancer. **2022**, 100169
- 529 Pre-diagnostic DNA methylation in blood leucocytes in cutaneous melanoma; a nested case-control study within the Norwegian Women and Cancer cohort. **2022**, 12,
- 528 PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. **2022**, 12,
- 527 CHIPing away the progression potential of CHIP: A new reality in the making. **2022**, 101001 0

526	Centuries of genome instability and evolution in soft-shell clam transmissible cancer.	0
525	Hepatocellular carcinoma in Mongolia delineates unique molecular traits and a mutational signature associated with environmental agents.	0
524	Considerations for carcinogenesis countermeasure development using mouse models. 2022,	0
523	A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer. 13,	1
522	APOBEC-Induced Mutagenesis in Cancer. 2022, 56,	1
521	Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73. 2022,	
520	Analytical Principles of Cancer Next Generation Sequencing. 2022,	2
519	Mutational signatures and increased retrotransposon insertions in Xeroderma Pigmentosum variant skin tumors.	
518	Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively. Publish Ahead of Print,	0
517	Optimal Cancer Evasion in a Dynamic Immune Microenvironment.	0
516	Patterns of structural variation define prostate cancer across disease states.	
515	The evolution of two transmissible leukaemias colonizing the coasts of Europe.	0
514	Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. 12,	0
513	Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. 2022, 14,	0
512	Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. 2022, 13,	1
511	Distinct non-clock-like signatures of the basal cell carcinomas from three sisters with a lethal Gorlin-Goltz syndrome. 2022, 15,	
510	Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report. Volume 15, 883-890	0
509	A mutation rate model at the basepair resolution identifies the mutagenic effect of Polymerase III transcription.	

- 508 Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report. 13, 0
- 507 Differential roles and regulation of the protein kinases PAK4, PAK5 and PAK6 in melanoma cells.
- 506 Neoadjuvant immunotherapy of locoregionally advanced solid tumors. **2022**, 10, e005036 0
- 505 Predicting regional somatic mutation rates using DNA motifs.
- 504 Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. **2022**, 13,
- 503 Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management.
- 502 Panel Sequencing for Targeted Therapy Selection in Solid Tumors. **2022**,
- 501 Treatment Resistance to Melanoma Therapeutics on a Single Cell Level.
- 500 Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts. **2022**, 5, 1
- 499 Clonal evolution during metastatic spread in high-risk neuroblastoma. 0
- 498 Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. **2022**, 10, 52 1
- 497 Lynch Syndrome: From Carcinogenesis to Prevention Interventions. **2022**, 14, 4102 0
- 496 Immunotherapeutic targets in non-small cell lung cancer. 1
- 495 Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure.
- 494 Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma. **2022**, 22, 1
- 493 Loss of genes in chromosome arms 5q and 16q in breast cancer. **2022**, 41, 331-341
- 492 Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. **2022**, 12, e058692 0
- 491 Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. 13, 1

- 490 Association of FLG mutation with tumor mutation load and clinical outcomes in patients with gastric cancer. 13, 1
- 489 The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. **2022**, 101, e29715
- 488 The butterfly effect: mutational bias of SARS-CoV-2 affects its pattern of molecular evolution on synonymous and nonsynonymous levels.
- 487 Multi-omics characterization reveals the pathogenesis of liver focal nodular hyperplasia. **2022**, 25, 104921
- 486 Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. **2022**, 172, 19-28 1
- 485 Carcinogenesis induced by space radiation: A systematic review. **2022**, 32, 100828 1
- 484 Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. **2022**, 1868, 166516
- 483 Leukemias, Lymphomas, and Plasma Cell Disorders. **2023**, 237-300
- 482 Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. 11, 0
- 481 Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms tumor. 0
- 480 RESISTOR: A New OSPREY Module to Predict Resistance Mutations. 0
- 479 Recurrent or primary metastatic cervical cancer: current and future treatments. **2022**, 7, 100579 1
- 478 Exploring ABOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer. **2022**, 25, 105077 0
- 477 Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. **2022**, 0
- 476 Genomic Alterations in Lung Cancer. **2022**, 0
- 475 Genetics of Pancreatic Carcinogenesis: Current Molecular Insights from Animal Models. **2022**, 1-24 0
- 474 SNPs Ability to Influence Disease Risk: Breaking the Silence on Synonymous Mutations in Cancer. **2022**, 77-96 0
- 473 Insights into functional connectivity in mammalian signal transduction pathways by pairwise comparison of protein interaction partners of critical signaling hubs. **2022**, 13, 298-313 0

472	Introduction to various types of cancers. 2022 , 1-29	2
471	Ferroptosis-Related Long Noncoding RNAs Have Excellent Predictive Ability for Multiomic Characteristics of Bladder Cancer. 2022 , 2022, 1-30	0
470	Whole-Exome Sequencing Reveals the Genomic Features of the Micropapillary Component in Ground-Glass Opacities. 2022 , 14, 4165	0
469	New Biomarkers and Immunotherapy Decision. 2022 , 1-15	0
468	Homologous Recombination Deficiency Scar: Mutations and Beyond Implications for Precision Oncology. 2022 , 14, 4157	0
467	Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes.	0
466	Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity. 2022 ,	0
465	UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma. 2022 , 12, 1339	0
464	Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas. 2022 , 14,	0
463	African-specific molecular taxonomy of prostate cancer. 2022 , 609, 552-559	1
462	Diffuse Large B-Cell Lymphomas: From Morphology to Genomic Profiling.	0
461	Prognostic role of indoleamine 2,3-dioxygenase 1 expression in solid tumors: A systematic review and meta-analysis. 12,	0
460	Identification of Shared Neoantigens in BRCA1-Related Breast Cancer. 2022 , 10, 1597	1
459	A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.	0
458	Single-cell genome sequencing of human neurons identifies somatic point mutation and indel enrichment in regulatory elements. 2022 , 54, 1564-1571	2
457	The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations. 2022 , 17, e0274383	0
456	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. OF1-OF10	0
455	BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. 2022 ,	0

454	Editorial: Immunotherapy for Prostate Cancer ¶turning the immunological desert into an oasis of hope. 12,	0
453	De novo mutations, genetic mosaicism and human disease. 13,	1
452	Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models. 2022 , 24,	0
451	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. 2022 , 14, 4751	1
450	Signatures 1 and 17 show increased propensity to create mutational hotspots in the human genome.	1
449	The mutational signatures of formalin fixation on the human genome. 2022 , 13,	1
448	Divergence of mutational signatures in association with breast cancer subtype.	1
447	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. 2022 , 41,	4
446	Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: first two cases with clinicopathologic and molecular comparison to eight visceral counterparts.	0
445	Molecular subtyping of SCLC based on mutational signatures with different genomic features and therapeutic strategies.	0
444	Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. 2022 , 21,	0
443	DEText: An SNV detection enhancement for low read depth by integrating mutational signatures into TextCNN. 13,	0
442	HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. 13,	0
441	UVA Radiation, DNA Damage, and Melanoma. 2022 , 7, 32936-32948	3
440	APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway. 12,	0
439	Small-Angle X-ray Scattering (SAXS) Measurements of APOBEC3G Provide Structural Basis for Binding of Single-Stranded DNA and Processivity. 2022 , 14, 1974	0
438	Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.	0
437	Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma.	0

436	Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma. 13,	0
435	de novo variant calling identifies cancer mutation signatures in the 1000 Genomes Project.	0
434	Individual Genetic Heterogeneity. 2022 , 13, 1626	0
433	Mutational Signatures as Sensors of Environmental Exposures: Analysis of Smoking-Induced Lung Tissue Remodeling. 2022 , 12, 1384	0
432	The Drivers, Mechanisms, and Consequences of Genome Instability in HPV-Driven Cancers. 2022 , 14, 4623	0
431	Somatic Mutational Landscape in Mexican Patients: CDH1 Mutations and chr20q13.33 Amplifications Are Associated with Diffuse-Type Gastric Adenocarcinoma. 2022 , 23, 11116	0
430	Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma. 2022 , 10, e005136	1
429	Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.	2
428	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. 2022 , 100179	4
427	Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient HCC.	0
426	Mutagenic Characteristics of Six Heavy Metals in Escherichia coli: The Commonality and Specificity. 2022 , 56, 13867-13877	0
425	Exploratory genomic analysis of high grade neuroendocrine neoplasms across diverse primary sites. 2022 ,	0
424	Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. 2022 , 10, e004913	0
423	Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer. 13,	0
422	A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma. 13,	0
421	A mitochondria-specific mutational signature of aging: increased rate of A >G substitutions on the heavy strand.	2
420	Clinical Outcome-Related Cancer Pathways and Mutational Signatures in Patients With Unresectable Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy. 2022 ,	0
419	L1 retrotransposition is regulated post-transcriptionally In High-Grade Serous Ovarian Cancer.	0

418	Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. 2022 , 14, 4631	1
417	Genomic landscape of lung adenocarcinomas in different races. 12,	0
416	Effects of replication domains on genome-wide UV-induced DNA damage and repair. 2022 , 18, e1010426	0
415	Big data in basic and translational cancer research.	3
414	An RNA link for METTL16 and DNA repair in PDAC. 2022 , 3, 1018-1020	0
413	Quantification of APOBEC3 Mutation Rates Affecting the VP1 Gene of BK Polyomavirus In Vivo. 2022 , 14, 2077	0
412	The genomic landscape of pediatric acute lymphoblastic leukemia. 2022 , 54, 1376-1389	7
411	Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. 2022 , 14, 2033	0
410	DrepmeIA Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment. 2022 , 11, 2894	0
409	Genetic analysis of low-grade adenosquamous carcinoma of the breast that progressed to high-grade metaplastic carcinoma.	0
408	Molecular Biomarkers of Response to Cancer Immunotherapy. 2022 , 42, 469-484	0
407	A newly defined basement membrane-related gene signature for the prognosis of clear-cell renal cell carcinoma. 13,	0
406	Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung. 12,	0
405	APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. 2022 ,	0
404	The cytidine deaminase APOBEC3G drives cancer mutagenesis and clonal evolution in bladder cancer.	0
403	Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia. Publish Ahead of Print,	0
402	Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications. 2022 , 14, 4653	0
401	Shifts in mutation bias promote mutators by altering the distribution of fitness effects.	2

400	Intrinsic base substitution patterns in diverse species reveal links to cancer and metabolism.	0
399	The Predictive Effect of Tumor Mutation Burden on prognosis in Breast cancer: A Systematic Review and Meta-Analysis.	0
398	Genomics of PDGFR-rearranged hypereosinophilic syndrome.	0
397	Tumor mutational burden by whole-genome sequencing in resected NSCLC of never smokers.	0
396	Hidden Markov Modelling for Biological Sequence. 2023 , 383-403	0
395	Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.	1
394	DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer. 13,	0
393	Complex genomic patterns of abasic sites in mammalian DNA revealed by a high-resolution SSiNGLe-AP method. 2022 , 13,	0
392	Genomic profiling with whole-exome sequencing revealed distinct mutations and novel pathways in Asian melanoma.	0
391	Characterization of the evolution trajectory and immune profiling of new histologic patterns in lung adenocarcinoma.	0
390	Oncogenic Merkel cell polyomavirus T antigen truncating mutations are mediated by APOBEC3 activity in Merkel cell carcinoma.	0
389	Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. Volume 15, 1105-1117	1
388	Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective. 2022 , 215945	0
387	Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.	0
386	Causes, consequences and clinical significance of aneuploidy across melanoma subtypes. 12,	0
385	Deep Learning model accurately classifies metastatic tumors from primary tumors based on mutational signatures.	0
384	Non-genomic activation of the AKT-mTOR pathway by the mitochondrial stress response in thyroid cancer.	0
383	Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. 2022 , 13,	1

- 382 Functional genomics of complex cancer genomes. **2022**, 13, 0
- 381 Role of AI and digital pathology for colorectal immuno-oncology. 2
- 380 The clinical utility of dysregulated microRNA expression in paediatric solid tumours. **2022**, 176, 133-154 0
- 379 Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program **HERO** **2022**, 175, 311-325 0
- 378 CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment. **2022**, 21, 153303382211320 0
- 377 Melanoma. **2022**, 295-346 0
- 376 Histologic transformation in lung cancer: when one door shuts, another opens. **2022**, 14, 175883592211305 0
- 375 The Prospects of Immunotherapy in Pancreatic Cancer. **2022**, 269-281 0
- 374 Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors. **2022**, 14, 4804 0
- 373 Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience. **2022**, 10, 2528 1
- 372 The Tumor Microenvironment of Medulloblastoma: An Intricate Multicellular Network with Therapeutic Potential. **2022**, 14, 5009 1
- 371 DUSP5 and PHLDA1 mutations in mature cystic teratomas of the ovary identified on whole-exome sequencing may explain teratoma characteristics. **2022**, 16, 0
- 370 Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. 0
- 369 A simple approach for detecting HLA-A *02 alleles in archival formalin-fixed paraffin-embedded tissue samples and an application example for studying cancer immunoediting. 0
- 368 Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). **2022**, 12, 205-216 0
- 367 Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer. 11, 0
- 366 How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. **2022**, 10, 2498 1
- 365 Chromosomal Instability, Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity. **2022**, 14, 4986 1

364	Amplification, Enrichment, and Sequencing of Mutagenic Methylated DNA Adduct through Specifically Pairing with Unnatural Nucleobases.	0
363	Research on the influence of APOBEC family on the occurrence, diagnosis, and treatment of various tumors.	0
362	Cancer Genomics and Evolution. 1-30	0
361	Sensitization of Patient-Derived Colorectal Cancer Organoids to Photon and Proton Radiation by Targeting DNA Damage Response Mechanisms. 2022 , 14, 4984	0
360	COL22A1 and DNAH8 mutations are associated with tumor mutation burden and prognosis of lung adenocarcinoma patients.	0
359	Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies. 2022 , 14,	0
358	Redistribution of mutation rates across chromosomal domains in human cancer genomes.	0
357	COOBoostR: an extreme gradient boosting-based tool for robust tissue or cell-of-origin prediction of tumors.	0
356	Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer.	0
355	Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response. 2022 , 8,	1
354	Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.	1
353	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. 2022 , 3, 1181-1191	1
352	Molecular Skin Cancer Diagnosis. 2022 ,	2
351	Activation induced cytidine deaminase: An old friend with new faces. 13,	3
350	Mono- and biallelic germline variants of DNA glycosylase genes in colon adenomatous polyposis families from two continents. 12,	0
349	The Mutagenic Consequences of DNA Methylation within and across Generations. 2022 , 6, 33	1
348	Precision Medicine in Oncology Drug Development. 1-15	0
347	Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. 2022 , 9,	0

346	Preliminary study on the molecular features of mutation in multiple primary oral cancer by whole exome sequencing. 12,	0
345	Immune-Checkpoint-Inhibitor Therapy Principles and Relevance of Biomarkers for Pathologists and Oncologists. Publish Ahead of Print,	0
344	Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma. 2022 , 2022, 1-40	1
343	In vitro germ cell induction from fertile and infertile monozygotic twin research participants. 2022 , 3, 100782	0
342	Single-cell genomic variation induced by mutational processes in cancer.	3
341	Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. 2022 , 13, 830-843.e3	0
340	Mechanisms of Cancer Metastasis. 2022 ,	2
339	MYC and therapy resistance in cancer: risks and opportunities. 2022 , 16, 3828-3854	0
338	The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. 2022 , 21, 1645-1651	1
337	The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. 12,	2
336	Predicting prognosis and immunotherapeutic response of clear cell renal cell carcinoma. 13,	0
335	Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer. 2022 , 14, 4858	1
334	Gene panel testing detects important genetic alterations in ulcerative colitis-associated colorectal neoplasia. 2022 , 24,	0
333	Cancérogénèse et variants faux sens pathogéniques du domaine exonucléotidique des ADN polymérase β et γ 2022 , 38, 763-765	0
332	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. 12,	0
331	A comparison of DNA sequencing and gene-expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.	0
330	Expanding biomarkers for PARP inhibitors. 2022 , 3, 1141-1143	0
329	Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma.	0

328	How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. 2022 , 58, 1386	0
327	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. 13,	1
326	Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.	1
325	Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma. 2022 , 14, 5325	0
324	8-Oxoguanine: from oxidative damage to epigenetic and epitranscriptional modification.	1
323	Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. 2022 , 36, 2734-2738	0
322	The co-evolution of the genome and epigenome in colorectal cancer.	3
321	Excerno: Using Mutational Signatures in Sequencing Data to Filter False Variants Caused by Clinical Archival.	0
320	DISRUPTOR: Computational identification of oncogenic mutants disrupting protein interactions.	0
319	Identification of natural product 3, 5-diodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression. 2022 , 10, e005503	0
318	APOBEC3G protects the genome of human cultured cells and mice from radiation-induced damage.	0
317	Esophageal Cancer Genetics and Clinical Translation. 2022 , 32, 425-435	0
316	Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect. 2022 , 352, 328-337	0
315	Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing. 2022 , 135, 106218	0
314	DNA Methyltransferases and DNA Damage. 2022 , 349-361	0
313	Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers. 2022 , 13,	0
312	Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. 12,	1
311	APOBEC3A /B deletion polymorphism and endometrial cancer risk.	0

310	Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. 2022 , 13,	1
309	Genomic characterization of intracranial teratomas using whole genome sequencing. 12,	0
308	The bromodomain protein TRIM28 controls the balance between growth and invasiveness in melanoma.	0
307	Evaluating multiple next-generation sequencing derived tumor features to accurately predict DNA mismatch repair status. 2022 ,	0
306	External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.	0
305	M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma. 2022 , 22,	0
304	Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. 2022 , 14, 5431	0
303	Unsupervised Pharmaceutical Polymorph Identification and Multicomponent Particle Mapping of ToF-SIMS Data by Non-Negative Matrix Factorization.	0
302	Das periokuläre Merkel-Zell-Karzinom – eine Übersicht klinischer Aspekte und aktueller Therapieoptionen.	0
301	The repertoire of copy number alteration signatures in human cancer.	1
300	The impact of paternal age on new mutations and disease in the next generation. 2022 ,	0
299	Current developments in gastric cancer: from molecular profiling to treatment strategy.	2
298	Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer. 2022 , 108445	0
297	Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: results of the EORTC SPECT-AYA international proof-of-concept study.. 2022 ,	0
296	Cancer classification based on multiple dimensions: SNV patterns. 2022 , 151, 106270	0
295	Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response. 2022 , 87, 117-126	0
294	Monitoring APOBEC3A protein levels in human cancer cells. 2022 ,	0
293	Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring.	0

292	HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy. 2022 , 13,	0
291	The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. 2022 , 22,	1
290	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. 2022 , 24,	0
289	Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma. 2022 , 14,	1
288	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. 2022 , 895-915	0
287	Immunotherapy for brain metastases and primary brain tumors. 2023 , 179, 113-120	0
286	Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. 2023 , 112, 102498	0
285	The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization. 2023 , 33, 1-11	0
284	The mutational impact of Illudin S on human cells. 2023 , 122, 103433	0
283	Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. 2023 , 169, 98-105	0
282	Shifting Treatment Paradigms in Non-Hodgkin Lymphomas. 35-43	0
281	Statistical Challenges in Mutational Signature Analyses of Cancer Sequencing Data. 2022 , 241-258	0
280	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. 2022 , 7, 131-149	1
279	Copy number footprints of platinum-based anticancer therapies.	0
278	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. 2022 , 14, 5858	0
277	Integrated multi-omics Landscape of liver metastases. 2022 ,	1
276	Targeted Therapy for Melanomas Without BRAF V600 Mutation. 2022 , 24, 1873-1881	0
275	Competition for DNA binding between the genome protector replication protein A and the genome modifying APOBEC3 single-stranded DNA deaminases. 2022 , 50, 12039-12057	1

- 274 Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability. **2022**, 129, 14-22 ○
- 273 Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers. **2022**, 12, ○
- 272 The Somatic Mutation Landscape of UDP-Glycosyltransferase (UGT) Genes in Human Cancers. **2022**, 14, 5708 ○
- 271 DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. **2022**, 23, 14672 ○
- 270 PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. **2022**, 20, 1
- 269 Advances in the understanding and treatment of Cutaneous T-cell Lymphoma. 12, ○
- 268 T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC). **2022**, 14, 5883 ○
- 267 Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. **2022**, 13, ○
- 266 Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. **2022**, 14, 5679 ○
- 265 Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. **2022**, ○
- 264 Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma. **2022**, 15, ○
- 263 Regional mutational signature activities in cancer genomes. **2022**, 18, e1010733 ○
- 262 Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data. **2022**, 22, ○
- 261 Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells. **2022**, 12, ○
- 260 Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis. **2022**, ○
- 259 Primary mucosal melanomas of the head and neck are characterised by overexpression of the DNA mutating enzyme APOBEC3B. 1
- 258 Identification of multiplicatively acting modulatory mutational signatures in cancer. **2022**, 23, ○
- 257 Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors. 11, ○

- 256 Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer. **2022**, 43, 201-209 ○
- 255 The OSUMMER lines: a series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6. ○
- 254 Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. **2023**, 15, 18 ○
- 253 Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. **2022**, 41, 111859 ○
- 252 The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment. 12, ○
- 251 Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors. ○
- 250 Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response. **2022**, 6, ○
- 249 The BRCAness Landscape of Cancer. **2022**, 11, 3877 1
- 248 Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. ○
- 247 Clinical and genomic characterization of mutational signatures across human cancers. ○
- 246 What do cancer specific T cells see? ○
- 245 A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. **2022**, 2022, 1-19 ○
- 244 Neoadjuvant immunotherapy for resectable esophageal cancer: A review. 13, ○
- 243 Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma. **2022**, 110565 ○
- 242 Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images. **2022**, 3, 100872 2
- 241 Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. **2023**, 15, 48 1
- 240 Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. **2022**, 7, 100611 ○
- 239 A Combined Risk Score Model to Assess Prognostic Value in Patients with Soft Tissue Sarcomas. **2022**, 11, 4077 ○

238	An integrative approach for exploring the nature of fibroepithelial neoplasms.	0
237	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. 2022 , 14, 6034	1
236	Cancer Genomics. 2022 , 53, 723-731	1
235	Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.. 2022 ,	0
234	The Impact of DFT Functional, Cluster Model Size, and Implicit Solvation on the Structural Description of Single-Metal-Mediated DNA Phosphodiester Bond Cleavage: The Case Study of APE1. 2022 , 126, 10672-10683	0
233	Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. 2022 , 11, 7259	0
232	EBV Association with Lymphomas and Carcinomas in the Oral Compartment. 2022 , 14, 2700	0
231	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. 13,	2
230	Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing for personalized oncology.	0
229	Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia. 13,	0
228	Structure-Guided Design of a Potent and Specific Inhibitor against the Genomic Mutator APOBEC3A. 2022 , 17, 3379-3388	1
227	BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network.	0
226	The Current Management of Merkel Carcinoma of the Head and Neck: a Scoping Review. 2023 , 5,	0
225	Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer. 2023 , 40,	0
224	Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. 2023 , 7,	1
223	Biomaterials assisted construction of neoantigen vaccines for personalized cancer immunotherapy.	0
222	Arginine limitation causes a directed DNA sequence evolution response in colorectal cancer cells.	0
221	Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. 2023 , 4, 100900	0

- 220 Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. **2023**, 11, e005801
- 219 Review: The Key Factors to Melanomagenesis. **2023**, 13, 181
- 218 Squamous Cell Carcinoma of Head and Neck.
- 217 Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers.
- 216 Programmed Cell Death Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer: Findings from a tertiary care institute in western part of India. **2023**,
- 215 Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics. rna.079498.122
- 214 A Bayesian model for unsupervised detection of RNA splicing based subtypes in cancers. **2023**, 14,
- 213 Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?. 12,
- 212 Identification and Validation of Necroptosis-Related Gene Signatures to Predict Clinical Outcomes and Therapeutic Responses in Acute Myeloid Leukemia.
- 211 The maximum tumor growth rate predicts clinical outcomes of patients with small-cell lung cancer undergoing first-line chemotherapy plus immune-checkpoint inhibitor therapy.
- 210 Characterization of Pancreatic Cancer with Ultra-low Tumor Mutational Burden.
- 209 A Universal Antigen-Ranking Method to Design Personalized Vaccines Targetting Neoantigens against Melanoma. **2023**, 13, 155
- 208 Characterization and outcome of RAC1 mutated melanoma. **2023**,
- 207 Whole-Genome Sequencing Reveals Mutational Signatures Related to Radiation-Induced Sarcomas and DNA-Damage-Repair Pathways. **2023**, 36, 100004
- 206 DeepSom: a CNN-based approach to somatic variant calling in WGS samples without a matched normal. **2023**, 39,
- 205 Strahlentherapie und Immuntherapie. **2023**, 1-20
- 204 Comparative genomic analysis of esophageal squamous cell carcinoma among different geographic regions. 12,
- 203 DNA damage and somatic mutations in mammalian cells after irradiation with a nail polish dryer. **2023**, 14,

202	Role of gene signature regulation in tumor immune microenvironment on the mechanism of uveal melanoma metastasis. 2023 , 1-15	0
201	Whole-exome sequencing revealed the mutational profiles of primary central nervous system lymphoma. 2023 ,	0
200	Unravelling the instability of mutational signatures extraction via archetypal analysis. 13,	0
199	S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas. 2023 , 36, 100874	0
198	Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma. 2023 , 15, 272	2
197	Malignant DFFB isoform switching promotes leukemia survival in relapse pediatric T-cell acute lymphoblastic leukemia.	0
196	Predicting Tumor Mutation Burden of TNBC Based on Nuclei Scores of Histopathological Images. 2022 ,	0
195	COOBoostR: An Extreme Gradient Boosting-Based Tool for Robust Tissue or Cell-of-Origin Prediction of Tumors. 2023 , 13, 71	0
194	Rise of the natural red pigment βrodigosin as an immunomodulator in cancer. 2022 , 22,	0
193	Comparative genetic profiling of neuroblastoma at the onset vs recurrence or progression of the tumor and determination of the prognostic role of genetic alterations. 2022 , 21, 18-30	0
192	Deubiquitinase ubiquitin-specific protease 3 (USP3) inhibits HIV-1 replication via promoting APOBEC3G (A3G) expression in both enzyme activity-dependent and -independent manners. Publish Ahead of Print,	0
191	Identification of personalized driver genes for individuals using graph convolution network. 2022 ,	0
190	CRISPR engineering in organoids for gene repair and disease modelling. 2023 , 1, 32-45	0
189	Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells. 2023 , 9,	1
188	Deciphering gene contributions and etiologies of somatic mutational signatures of cancer.	0
187	Molecular profiling of primary uveal melanoma: results of a Polish cohort. Publish Ahead of Print,	0
186	Pathological consequences of DNA damage in the kidney.	0
185	Genetics of Pancreatic Carcinogenesis: Current Molecular Insights from Animal Models. 2023 , 591-614	0

184	Tumor immunology. 2023 , 245-452	0
183	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. 2023 ,	0
182	Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. 2023 , 5,	1
181	mSigHdp: hierarchical Dirichlet process mixture modeling for mutational signature discovery. 2023 , 5,	0
180	Epigenetic-Metabolic Interplay in the DNA Damage Response and Therapeutic Resistance of Breast Cancer.	0
179	Advances in Natural Killer Cells and Immunotherapy for Gastric Cancer.	0
178	Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis (BCLM) reveals acquisition of a lobular-like phenotype.	0
177	Pan-cancer analysis of chromothripsis-related gene expression patterns indicates an association with tumor immune and therapeutic agent responses. 13,	0
176	Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers.	0
175	Base editing screens map mutations affecting interferon- β signaling in cancer. 2023 ,	0
174	Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. 14,	0
173	A Comprehensive Analysis of Cutaneous Melanoma Patients in Greece Based on Multi-Omic Data. 2023 , 15, 815	0
172	Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancy.	0
171	IL-15 Prevents the Development of T-ALL from Aberrant Thymocytes with Impaired DNA Repair Functions and Increased NOTCH1 Activation. 2023 , 15, 671	1
170	Translational aspects of photodynamic therapy in drug-resistant cancer. 2023 , 459-488	0
169	Powering Toxicogenomic Studies by Applying Machine Learning to Genomic Sequencing and Variant Detection. 2023 , 611-627	0
168	APOBEC mutagenesis is a common process in normal human small intestine.	0
167	Proteogenomics decodes the evolution of human ipsilateral breast cancer. 2023 , 6,	1

- 166 Clinically relevant concurrent BRAF and MEK inhibition alters differentiation states and sensitizes BRAF V600E-mutated high-grade gliomas to immune checkpoint blockade. ○
- 165 Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma. **2023**, 154, 106602 ○
- 164 Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. **2023**, ○
- 163 The role of APOBEC3A in cervical cancer development and progression: A retrospective study. **2023**, ○
- 162 The Q-IMPROVE (Queensland-Implementation of PRrecision Oncology in brEast cancer) pilot study. ○
- 161 Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. 14, ○
- 160 Beyond the Genetic Code:A Tissue Code?. ○
- 159 PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. 14, ○
- 158 Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer. ○
- 157 Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study. 13, ○
- 156 A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers. **2023**, 116, 109821 ○
- 155 In situ analysis of immune checkpoint molecule on bladder cancer cell based on cellular interface supported cascade signal amplification mediated by CRISPR/Cas13a system. **2023**, 133784 ○
- 154 Genetic modifiers of APOBEC-induced mutagenesis. ○
- 153 Oncogenic drivers dictate immune control of acute myeloid leukemia. **2023**, 14, ○
- 152 Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies. 14, ○
- 151 Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling. ○
- 150 Alpha-ketoglutarate as a potent regulator for lifespan and healthspan: Evidences and perspectives. **2023**, 175, 112154 ○
- 149 HTLV-1 bZIP factor impairs DNA mismatch repair system. **2023**, 657, 43-49 ○

- 148 Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. **2023**, 69, 330-341 ○
- 147 Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. **2023**, 26, 169-180 ○
- 146 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. 29, 2241-2260 ○
- 145 Molecular characterization of visible low-grade dysplastic lesions in patients with inflammatory bowel disease. **2023**, 135, 108-116 ○
- 144 Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. **2022**, 1-34 ○
- 143 Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms. **2023**, 126, 107020 ○
- 142 Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. **2022**, 14, 1427-1448 ○
- 141 Melanome der Haut und Schleimhaut. **2022**, 205-236 ○
- 140 Multi-antigen spherical nucleic acid cancer vaccines. ○
- 139 APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors. ○
- 138 Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia. **2023**, 30, 153-170.e9 2
- 137 Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immuno-oncologic Predictive Factors. **2023**, 30, 203-210 ○
- 136 Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. 13, ○
- 135 Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance. **2023**, 14, 1 ○
- 134 The APOBEC3B cytidine deaminase is an adenovirus restriction factor. **2023**, 19, e1011156 ○
- 133 Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study. ○
- 132 The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. **2023**, 24, 3226 ○
- 131 Rad51 filaments assembled in the absence of the complex formed by the Rad51 paralogs Rad55 and Rad57 are outcompeted by translesion DNA polymerases on UV-induced ssDNA gaps. **2023**, 19, e1010639 ○

- 130 Using temporal heatmaps to identify worthwhile articles on immune checkpoint blockade for melanoma (ICBM) in Mainland China, Hong Kong, and Taiwan since 2000: A bibliometric analysis. **2023**, 102, e32797 ○
- 129 Immunotherapies validēs en oncogynēologie. **2023**, 110, 395-401 ○
- 128 Translocations and Gene Fusions in Sinonasal Malignancies. **2023**, 25, 269-278 ○
- 127 MiRNAgene network embedding for predicting cancer driver genes. ○
- 126 Immunotherapies against HER2-Positive Breast Cancer. **2023**, 15, 1069 ○
- 125 Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. 12, ○
- 124 Oncogenic drivers dictate immune control of acute myeloid leukemia. ○
- 123 Spatial genomic diversity associated with APOBEC mutagenesis in squamous cell carcinoma arising from ovarian teratoma. ○
- 122 Copy number footprints of platinum-based anticancer therapies. **2023**, 19, e1010634 ○
- 121 Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. **2023**, 15, 1 ○
- 120 Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. **2023**, ○
- 119 Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK). **2023**, 24, 3743 ○
- 118 Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer. **2023**, 83, 487-488 ○
- 117 Spatiotemporally controllable diphtherin transgene system and neoantigen immunotherapy. **2023**, 355, 538-551 ○
- 116 Immune-related risk score: An immune-cell-pair-based prognostic model for cutaneous melanoma. 14, ○
- 115 Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research. **2023**, 13, 553 ○
- 114 Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. **2023**, 15, 547 ○
- 113 LncRNA and its role in gastric cancer immunotherapy. 11, ○

- 112 Widespread perturbation of ETS factor binding sites in cancer. **2023**, 14, ○
- 111 Tracking the evolution of esophageal squamous cell carcinoma under dynamic immune selection by multi-omics sequencing. **2023**, 14, ○
- 110 Using comprehensive genomic and functional analyses for resolving genotype-phenotype mismatches in children with suspected CMMRD in Lebanon: an IRRDC study. **2023**, 142, 563-576 ○
- 109 The etiology of clonal mosaicism in human aging and disease. **2023**, 4, 3-20 ○
- 108 Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A. ○
- 107 Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. **2023**, 15, 1299 ○
- 106 Clinical Cancer Genomic Diagnostics and Modern Diagnostic Pathology. 1-13 ○
- 105 The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures. 12, ○
- 104 PMS2-associated Lynch syndrome: Past, present and future. 13, ○
- 103 Emerging roles of m6A RNA modification in cancer therapeutic resistance. **2023**, 12, ○
- 102 Current Trends in Mucosal Melanomas: An Overview. **2023**, 15, 1356 ○
- 101 The repertoire of copy number alteration signatures in human cancer. **2023**, 24, ○
- 100 Quantification and Mapping of Alkylation in the Human Genome Reveal Single Nucleotide Resolution Precursors of Mutational Signatures. **2023**, 9, 362-372 1
- 99 Error-corrected Duplex Sequencing enables direct detection and quantification of mutations in human TK6 cells with remarkable inter-laboratory consistency. ○
- 98 Generation of TGFB2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy. **2023**, 11, e006001 ○
- 97 Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology. ○
- 96 Arsenic is a potent co-mutagen of ultraviolet light. ○
- 95 Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. ○

- 94 Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes. **2023**, 21, ○
- 93 Predicting Cancer Risk from Germline Whole-exome Sequencing Data Using a Novel Context-based Variant Aggregation Approach. **2023**, 3, 483-488 ○
- 92 Detection and characterization of constitutive replication origins defined by DNA polymerase epsilon. **2023**, 21, ○
- 91 Deep learning predicts HRD and platinum response from histology slides in breast and ovarian cancer. ○
- 90 Building a precision medicine infrastructure at a national level: The Swedish experience. **2023**, 1, ○
- 89 LRT-CLUSTER: A New Clustering Algorithm Based on Likelihood Ratio Test to Identify Driving Genes. ○
- 88 Inhibitors targeting epigenetic modifications in cancer. **2023**, 287-324 ○
- 87 DNA Damage and Its Role in Cancer Therapeutics. **2023**, 24, 4741 ○
- 86 Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk. ○
- 85 Dynamics of 8-Oxoguanine in DNA: Decisive Effects of Base Pairing and Nucleotide Context. **2023**, 145, 5613-5617 ○
- 84 Regulatory roles of ferroptosis-related non-coding RNAs and their research progress in urological malignancies. 14, ○
- 83 PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma. **2023**, 21, ○
- 82 AI in Precision Medicine. **2023**, 200-209 ○
- 81 Clinical and genomic features of non-small cell lung cancer occurring in families. **2023**, 14, 940-952 ○
- 80 Vaccines as treatments for prostate cancer. ○
- 79 A Biterm Topic Model for Sparse Mutation Data. **2023**, 15, 1601 ○
- 78 LINC00261 expression reduces mutation accumulation while conferring resistance to cisplatin and altering the tumor-immune microenvironment in lung adenocarcinoma. ○
- 77 Mutational signatures in wild type Escherichia coli strains reveal dominance of DNA polymerase errors. ○

- 76 Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment. 14, ○
- 75 MR.DRP: A Parameter Adaptive Machine Learning Framework for Drug Response Prediction. **2022**, ○
- 74 MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression. 14, ○
- 73 Mitochondrial haplotype and mito-nuclear matching drive somatic mutation and selection throughout aging. 1
- 72 Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns. 12, ○
- 71 Prognosis and Characterization of Microenvironment in Cervical Cancer Influenced by Fatty Acid Metabolism-Related Genes. **2023**, 2023, 1-34 ○
- 70 Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humans. ○
- 69 Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report. **2023**, 34, 595-598 ○
- 68 The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity. **2023**, 5, ○
- 67 Strand asymmetries across genomic processes. **2023**, 21, 2036-2047 ○
- 66 Genotoxic colibactin mutational signature in colorectal cancer is associated with clinicopathological features, specific genomic alterations and better survival. ○
- 65 Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis. ○
- 64 Utilization of Functionalized Metal-Organic Framework Nanoparticle as Targeted Drug Delivery System for Cancer Therapy. **2023**, 15, 931 ○
- 63 Identification of prognostic m⁶A modification patterns and score system in melanoma patients. ○
- 62 Molecular Profile of MSH6-Associated Colorectal Carcinomas Shows Distinct Features From Other Lynch Syndrome-Associated Colorectal Carcinomas. **2023**, ○
- 61 An m⁷G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer. **2023**, 13, ○
- 60 Characterization of pancreatic cancer with ultra-low tumor mutational burden. **2023**, 13, ○
- 59 ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer. 13, ○

- 58 Update in the molecular classification of endometrial carcinoma. **2023**, 33, 333-342
- 57 Intestinal bacteria and colorectal cancer: etiology and treatment. **2023**, 15,
- 56 Age-related next-generation sequencing mutational analysis in 1196 melanomas.
- 55 Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers. **2023**, 13, 398
- 54 Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. **2023**, 1-19
- 53 Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. 13,
- 52 Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. **2023**, 244, 108387
- 51 Prospects of POLD1 in Human Cancers: A Review. **2023**, 15, 1905
- 50 High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. **2023**,
- 49 Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. **2023**, 7,
- 48 Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications. **2023**, 15, 1958
- 47 Perturbations in the ligand-receptor interactions unravel novel heterogeneous subtypes of stage II/III colorectal cancer.
- 46 Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia. **2023**, 14,
- 45 Analysis of evolutionary dynamics and clonal architecture in prostate cancer.
- 44 Multiancestry genomic and transcriptomic analysis of gastric cancer. **2023**, 55, 581-594
- 43 Top 10 Basaloid Neoplasms of the Sinonasal Tract. **2023**, 17, 16-32
- 42 Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens.
- 41 Mathematical modeling of neuroblastoma associates evolutionary patterns with outcomes. **2023**, 55, 530-531

- 40 Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches. **2023**, 63-81 ○
- 39 Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response. **2023**, 36, 100165 ○
- 38 Dissection of Cancer Mutational Signatures with Individual Components of Cigarette Smoking. **2023**, 36, 714-723 ○
- 37 APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. **2023**, 16, ○
- 36 Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes. **2023**, 14, ○
- 35 Bayesian Multi-Study Non-Negative Matrix Factorization for Mutational Signatures. ○
- 34 Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 14, ○
- 33 Mitochondrial H₂O₂ release does not directly cause genomic DNA damage. ○
- 32 Human DNA tumor viruses evade uracil-mediated antiviral immunity. **2023**, 19, e1011252 ○
- 31 Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors. OF1-OF8 ○
- 30 Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment. **2023**, 2023, 1-13 ○
- 29 Similar deamination activity but different phenotypic outcomes induced by APOBEC3 enzymes in breast epithelial cells. ○
- 28 Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma. ○
- 27 The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. **2023**, 24, 6710 ○
- 26 The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens. **2023**, 67, 101758 ○
- 25 Emerging predictive biomarkers in the management of bone and soft tissue sarcomas. 1-8 ○
- 24 Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. 13, ○
- 23 Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. ○

- 22 SARS-CoV-2 β evolutionary capacity is mostly driven by host antiviral molecules. ○
- 21 The APE2 nuclease is essential for DNA double-strand break repair by microhomology-mediated end joining. **2023**, ○
- 20 Genomic β transcriptomic evolution in lung cancer and metastasis. **2023**, 616, 543-552 ○
- 19 Genome-wide contributions of the MutS β and MutS α dependent DNA mismatch repair pathways to the maintenance of genetic stability in *S. cerevisiae*. **2023**, 104705 ○
- 18 Mesenchymal loss of p53 alters stem cell capacity and models human soft tissue sarcoma traits. **2023**, ○
- 17 Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. **2023**, 15, 2273 ○
- 16 BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. 13, ○
- 15 Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers. **2023**, 100190 ○
- 14 Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma. **2023**, 2023, 1-13 ○
- 13 First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis. **2023**, 19, 6 ○
- 12 No increase in translocated chromosomal aberrations, an indicator of ionizing radiation exposure, in childhood thyroid cancer in Fukushima Prefecture. ○
- 11 Validation of genetic variants from NGS data using deep convolutional neural networks. **2023**, 24, ○
- 10 The evolution of two transmissible cancers in Tasmanian devils. **2023**, 380, 283-293 ○
- 9 Changes in metabolic landscapes shape divergent but distinct mutational signatures and cytotoxic consequences of redox stress. ○
- 8 Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer. **2023**, 13, ○
- 7 Precision medicine: Overview and challenges to clinical implementation. **2023**, 513-529 ○
- 6 Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review. Volume 15, 281-294 ○
- 5 Late-stage MC38 tumours recapitulate features of human colorectal cancer β implications for appropriate timepoint selection in preclinical studies. 14, ○

- 4 Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. **2023**,
- 3 Protocol for predicting drug-resistant protein mutations to an ERK2 inhibitor using RESISTOR. **2023**, 4, 102170
- 2 Wee1 epigenetically modulates H2B mono-ubiquitination at K120 lysine and DNA double-strand break repair through phosphorylation of H2BY37 -dependent manner in small-cell lung cancer.
- 1 Model selection and robust inference of mutational signatures using Negative Binomial non-negative matrix factorization. **2023**, 24,